header logo image


Page 7«..6789..2030..»

Archive for April, 2020

Amish Genetic Disease Panel created by DDC Clinic can now test for 160 rare conditions – The Weekly Villager

Monday, April 27th, 2020

Middlefield Dr. Heng Wang, a board certified pediatrician and the Medical Director of the DDC Clinic located in Middlefield, OH, announced today that their Amish Genetic Disease Panel will now test for 160 rare conditions. This important tool allows faster diagnosis of unidentified genetic conditions at a reduced cost. DDC Clinic delivers personalized and life-changing medical care to special needs children affected by rare genetic disorders.

Were very excited to be able to now screen for an additional 40 conditions as part of this panel, said Dr. Wang. Early diagnosis leads to early treatments, and those effective treatments can be lifesaving.

Dr. Wang credited the hard work of his staff with bringing this project to fruition months ahead of schedule. This project was partially funded by the Elisabeth Severance Prentiss Foundation and the Fowler Family Foundation. Their support allows us to keep the cost of the new panel the same as the previous panel.

The improved Amish Genetic Disease Panel will be used in DDC Clinics collaboration with the Care Center in Middlefield. Parents of newborn infants at the birthing center can have a sample of their babys cord blood sent to DDC Clinic for analysis. Parents would then know if their child is affected by any of these 160 rare conditions. If a condition is identified, no additional testing would be needed and support services could be initiated early in the babys life. Thanks to our generous donors and the United Way of Geauga County, parents are asked to pay only $25.00 for this testing as part of their birthing fee.

The Amish Genetic Disease Panel has proven to be an important tool and is a great example of personalized medicine in action. It is a resource for doctors serving Amish and Mennonite patients in both Geauga County and neighboring communities.

Read the original post:
Amish Genetic Disease Panel created by DDC Clinic can now test for 160 rare conditions - The Weekly Villager

Read More...

Drug-gene testing could give experts insight into COVID-19 treatment – ModernHealthcare.com

Monday, April 27th, 2020

While researchers are working to advance drugs to treat COVID-19 and vaccines to give people immunity against the virus, the mental health impact of the pandemic will also have to be managed. This is where PGx testing may be most useful, experts in the field said.

"It is worthwhile to consider not just the utility of PGx in preventing hospitalization or changing the course of COVID-19 care," but also the impact it could have on managing "the burden on the patients that do survive a COVID-19 infection [and] those that are suffering from the isolation of social distancing, as well as the financial hardships," said David Thacker, a clinical pharmacogenetics content specialist at Translational Software.

According to a recent JAMA editorial, during the SARS outbreak in 2003, there was a greater incidence of post-traumatic stress syndrome and psychological distress among patients and doctors. In communities impacted by Hurricane Ike in 2008, around 5% of individuals met the criteria for major depressive disorder, while one in 10 adults in New York City had symptoms of the disorder after 9/11.

"In the context of the COVID-19 pandemic, it appears likely that there will be substantial increases in anxiety and depression, substance use, loneliness, and domestic violence; and with schools closed, there is a very real possibility of an epidemic of child abuse," wrote Sandro Galea from Boston University School of Public Health, Raina Merchant from the Perelman School of Medicine, and Nicole Lurie from the Coalition for Epidemic Preparedness Innovations in Norway.

A survey in March by the American Psychiatric Association found that more than a third of polled individuals said that the pandemic was seriously impacting their mental health, nearly half said they were scared about getting the virus, and 62% said they feared a loved one would get it. Meanwhile, calls to substance abuse and mental health help lines increased eightfold from February to March.

As the pandemic continues, people may increasingly turn to medications to deal with the psychological wounds left by the pandemic. Drugs to treat mental health conditions, including major depressive disorder, are some of the most widely prescribed drugs in the U.S., but they're also highly variable and associated with unwanted side effects.

As such, one of the main areas where PGx testing has seen uptake is for personalizing psychiatry drugs. Myriad Genetics recently published a meta-analysis involving more than 1,500 patients with major depressive disorder who were enrolled in four studies, which showed that patients who received treatment based on PGx information had significantly better outcomes than those who did not.

Although PGx testing in psychiatry is not without its naysayers, doctors may reach for such testing if the use of mental health drugs increases during or after the pandemic. Genomind, a mental health-focused PGx testing company, recently took a number of steps to make it easier for physicians to deliver psychiatric care during the pandemic. Doctors can order Genomind's PGx test and send a saliva collection kit to patient's homes, which can then be mailed to the lab for analysis. Through Genomind, doctors also have access to Sharecare's HIPAA-compliant telemedicine platform for free until September, which they can use to remotely see patients and discuss PGx test results, if ordered.

"The utility of PGx during the COVID-19 crisis is more important than ever," a spokesperson for the company said. "This service is helping enable critical mental health treatment during the pandemic and Genomind is doing its best to enable as many mental health professionals as possible."

This story first appeared in our sister publication, Genomeweb.

Read the rest here:
Drug-gene testing could give experts insight into COVID-19 treatment - ModernHealthcare.com

Read More...

CRISPR combines with stem cell therapy to reverse diabetes in mice – New Atlas

Monday, April 27th, 2020

For a few years now, scientists at Washington University have been working on techniques to turn stem cells into pancreatic beta cells as a way of addressing insulin shortages in diabetics. After some promising recent strides, the team is now reporting another exciting breakthrough, combining this technique with the CRISPR gene-editing tool to reverse the disease in mice.

The pancreas contains what are known as beta cells, which secrete insulin as a way of tempering spikes in blood-sugar levels. But in those with diabetes, these beta cells either die off or dont function as they should, which means sufferers have to rely on diet and or regular insulin injections to manage their blood-sugar levels instead.

One of the ways scientists are working to replenish these stocks of pancreatic beta cells is by making them out of human stem cells, which are versatile, blank slate-like cells that can mature into almost any type of cell in the human body. The Washington University team has operated at the vanguard of this technology with a number of key breakthroughs, most recently with a cell implantation technique that functionally cured mice with diabetes.

The researchers are continuing to press ahead in search of new and improved methods, and this led them to the CRISPR gene-editing system, which itself has shown real promise as a tool to treat diabetes. The hope was that CRISPR could be used to correct genetic defects leading to diabetes, combining with the stem cell therapy to produce even more effective results.

As a proof of concept, the scientists took skin cells from a patient with a rare genetic type of diabetes called Wolfram syndrome, which develops during childhood and typically involves multiple insulin injections each day. These skin cells were converted into induced pluripotent stem cells, which were in turn converted into insulin-secreting beta cells. But as an additional step, CRISPR was used to correct a genetic mutation that causes Wolfram syndrome.

These edited beta cells were then pitted against non-edited beta cells from the same batch in test tube experiments and in mice with a severe type of diabetes. The edited cells proved more efficient at secreting insulin and when implanted under the skin in mice, reportedly caused the diabetes to quickly disappear. The rodents that received the unedited beta cells remained diabetic.

This is the first time CRISPR has been used to fix a patients diabetes-causing genetic defect and successfully reverse diabetes, said co-senior investigator Jeffrey R. Millman. For this study, we used cells from a patient with Wolfram syndrome because, conceptually, we knew it would be easier to correct a defect caused by a single gene. But we see this as a stepping stone toward applying gene therapy to a broader population of patients with diabetes.

The researchers are now continuing to work on improving the beta cell production technique, which in the future could involve cells taken form the blood or even urine, rather than the skin. They believe that further down the track this therapy could prove useful in treating both type 1 and type 2 diabetes, by correcting mutations that arise from genetic and environmental factors, and possibly be used to treat other conditions, as well.

We basically were able to use these cells to cure the problem, making normal beta cells by correcting this mutation, said co-senior investigator Fumihiko Urano. Its a proof of concept demonstrating that correcting gene defects that cause or contribute to diabetes in this case, in the Wolfram syndrome gene we can make beta cells that more effectively control blood sugar. Its also possible that by correcting the genetic defects in these cells, we may correct other problems Wolfram syndrome patients experience, such as visual impairment and neurodegeneration.

The research was published in the journal Science Translational Medicine.

Source: Washington University

See more here:
CRISPR combines with stem cell therapy to reverse diabetes in mice - New Atlas

Read More...

Turkey’s top scientific body invests TL 2.3 billion on 16 vaccine projects over 5 years | Daily Sabah – Daily Sabah

Monday, April 27th, 2020

TBTAK has invested TL 2.3 billion ($ 300 million) for the development of 16 vaccine and other medicine projects over the past five years in Turkey, the president of the Scientific and Technological Research Council of Turkey (TBTAK) said Saturday.

A platform consisting of 41 Turkish institutions has mobilized to develop medicines and vaccines against COVID-19 pandemic, professor Hasan Mandal noted, adding that efforts to develop anti-coronavirus drugs and vaccines were launched late December in coordination with the Ministry of Industry and Technology and proposals to be carried out within a 9 to 12 month period were taken into account and evaluated.

There are 16 projects working in synergy both in medicine and vaccine groups thanks to the COVID-19 Turkey Platform, which includes 225 researchers from 25 universities, eight public research bodies and eight private firms, Mandal added.

For medicine in pre-clinical phases, we'll be in the production phase this summer, probably much earlier. For vaccine, pre-clinical phase will be completed within a nine-month period, Mandal said. He added that it is now time for institutions cooperating with the science body to prove their valor.

The modeling of molecules in the medicine group began with the identification of over 10,026 molecules that could provide a solution for this virus, Mandal explained, adding synthesis works regarding this and its production are now underway.

In order to fight with a virus that you recently came across, you have to know it and define it correctly. All proceeding phases are tied to this. For that, it should be isolated from all external conditions and genetic characterization of the virus should be carried out. We will have genetic characterization of this virus determined next week. This situation shows the competence of this country. We now know this virus and this will be among the most important indicators how we will fight it both on the medicine side and vaccine side, Mandal said.

Read more:
Turkey's top scientific body invests TL 2.3 billion on 16 vaccine projects over 5 years | Daily Sabah - Daily Sabah

Read More...

Paparazzi on the black pepper – Research Matters

Monday, April 27th, 2020

Researchers identify molecular markers that can help in developing better varieties of black pepper

Dubbed as the 'king of spices', black pepper has a lot to offerwhether as a flavouring agent or as a traditional medicine to relieve common cold, chest congestion or sore throat. A vital ingredient in many cuisines, it is the only spice that finds its way on nearly everything on the dining table. Piperine, a chemical in the black pepper, gives it a sharp taste. It is a native plant of the Western Ghats, and the crop is of immense agronomic value in today's world trade. However, insufficient genomic resources pose as main barriers in cultivating disease-resistant varieties of this master spice.

In a recent study, researchers from ICAR-National Bureau of Plant Genetic Resources, New Delhi, have identified a type of DNA sequence, called Simple Sequence Repeats (SSRs), which aims to ease and promote the genetic analysis of black pepper. The findings of the study, published in the journal PLoS ONE, could lead to enhanced productivity with better traits of the plant.

Simple Sequence Repeats, also called microsatellites, are repeating stretches of DNA that contain one to six nucleotide bases, and are randomly present throughout the genome. These can be passed from one generation to the next. Hence, they are used as a 'signpost' to keep track of a gene of interest. They play critical roles in genetic studies and plant breeding. The location of these SSRs in the genome remain the same in related species, thus enabling cost-effectiveness of similar studies on them.

Unlike other commercial crops like watermelon, cotton or finger millets, very few genetic studies have been done on black pepper, due to lack of resources. Although the Western Ghats harbours the maximum genetic diversity of black pepper, it remained "largely untouched from genomic interventions," say the researchers. The identification of cross-species SSRs will save time, effort and resources in the development of SSRs in these species, and aid future genetic and evolutionary studies.

The researchers first sequenced the entire genome isolated from the leaf samples of black pepper (Piper nigrum) and then scanned it for the presence of SSRs. The genome was then amplified with a method called Polymerase Chain Reaction, using short nucleic acid sequences called primers, designed to identify the right SSRs. The researchers compared the results of their analysis in thirty different types of black pepper. The researchers also explored ten species of Piper (including P. nigrum) for the presence of these SSRs by looking at an online database of the genetic sequence.

In all, 69,126 SSRs were identified in the study, with the majority of SSRs composed of two nucleotide repeatsthymine and adenosine (TA). Out of 85 primers, 74 produced the required results of appropriate-sized SSRs. Genetic diversity study of the thirty cultivars reported four distinct groups. A few SSRs were found in closely-related species, implying that they could be used in studying other species of black pepper with limited genomic knowledge.

The current study seeks to fill the void in genomic knowledge of black pepper species by identifying easy-to-detect molecular markers to enable its genetic and breeding studies. The SSRs, which indicate the location of a gene related to the desired trait, can help in choosing the right plants for breeding experiments, which is otherwise a difficult activity.

"The genomic microsatellite markers identified in black pepper in this study would form valuable and long-awaited resources for researchers and plant breeders", say the researchers.

The findings can also be used for diversity studies, linkage mapping, evolutionally biology, DNA fingerprinting and trait association shortly.

Originally posted here:
Paparazzi on the black pepper - Research Matters

Read More...

As Cuomo Issues New Executive Order, Weill Cornell Medicine Ramps Up COVID-19 Testing – Cornell University The Cornell Daily Sun

Monday, April 27th, 2020

As many people yearn to return to some form of normalcy, states are beginning to consider what the reopening of nonessential businesses should look like. In his daily press briefing Gov. Andrew Cuomo (D-N.Y.) said a crucial first step for reopening is widespread COVID-19 testing which New York State currently lacks.

On that same day, Dr. Augustine M.K. Choi, Weill Cornell Dean, announced a new initiative to begin antibody testing employees of Weill Cornell.

Current testing efforts across the state are focused on detecting those with the SARS-CoV-2 virus, but in order to begin reopening businesses people must be tested for previous exposure to the virus.

The current diagnostic used to test patients suspected of having COVID-19 at WCM is a real time reverse transcription polymerase chain reaction, an effective and relatively fast method to detect genetic material. It can be used to detect the RNA present in the SARS-CoV-2 virus.

PCR is the gold standard because its such a highly sensitive and specific test and can deliver reliable and accurate diagnosis in as fast as 2-5 hours. Compared to other available platforms its much faster and more accurate, said Dr. Melissa Cushing, pathology, in Chois update.

However, as institutions begin to test for people who were exposed to the virus and recovered, another method is required antibody testing. Instead of testing for the genetic material of the virus itself, antibody tests search for the antibodies that the body creates in response to COVID-19. These antibodies are formed between three and 15 days after experiencing symptoms, according to Cushing.

As of April 17, testing was made available for New York Presbyterian staff that tested positive for COVID-19 or had a COVID-19-like illness and returned to work.

WCM plans to make more testing available to its staff, as it works to increase its testing capabilities. Cushing predicted that this public testing is at least several weeks away. Experiencing the brunt of statewide shortages of certain materials, WCM also requires access to reagents and more high output platforms to increase its testing capabilities.

We need to really scale up with the amount of reagents we have with our current tests. Then we are really looking to some of the commercial labs to provide the large, high frequency platforms that we already use in our labs so that the process can be much more automated, Cushing said. That is our goal to be testing as many people that need to be tested in our city.

In order to address the testing insufficiencies on a statewide level, the governor issued an executive order on April 17 that directs all public and private labs capable of conducting virology testing to coordinate with the State Department of Health to prioritize coronavirus testing.

The testing and tracing is the guideposts through this. As we are working our way through the next several months the testing, which is informing us as to who can go back to work helping us isolate people, its about testing, Cuomo said in his daily briefing on April 17. Testing is a totally new challenge. Nobody has done this and what we need to do on testing.

According to Cuomo, the lack of infrastructure to facilitate widespread testing mirrors the earlier lack of coordination between hospitals, which the Surge and Flex initiative addressed the initiative coordinated the distribution of scarce medical supplies between public and private hospitals across the state.

Besides the lack of infrastructure, another impasse to wide scale testing is the availability of the materials specifically chemical reagents necessary to run the tests.

Currently, this order will not affect the labs on Cornells Ithaca campus.

Cornell University is not offering any human testing for COVID-19 on campus at this point. We will always follow all state/federal government regulations as appropriate, John Carberry, a University spokesperson, wrote in a statement to The Sun.

Cornell is affiliated with two of the 301 laboratories and hospitals capable of performing viral testing the Allyn B Ley Clinical Laboratory housed in Cornell Health and the Hospital for Special Surgery Dept of Pathology and Laboratory Medicine in New York City.

Initially, 28 laboratories with clinical laboratory permits from the state health department and experience in molecular-based virology could conduct testing. However, this system is unable to meet the demand for the widespread testing needed to reopen New York State.

We dont have a testing system that can do this volume, or that can be ramped up to do this volume. We dont have a public health testing system, its de minimis if you look at what our government department of health have, Cuomo said.

The state has begun its efforts to perform antibody tests on 3,000 individuals to better understand what percentage of the population is currently immune to the virus. The plan is being supported financially by former New York City mayor Michael Bloomberg, who pledged more than $10 million to create a test and trace program.

See original here:
As Cuomo Issues New Executive Order, Weill Cornell Medicine Ramps Up COVID-19 Testing - Cornell University The Cornell Daily Sun

Read More...

Drug companies are the good guys – MetroWest Daily News

Monday, April 27th, 2020

Many people dislike drug companies. Drug companies often charge a lot of money for their products. Sometimes their drugs dont work. Sometimes they have side effects. Sometimes they are addictive. Even the best drugs wont keep us alive forever.

But, during the coronavirus pandemic, we are relying on drug companies and other healthcare companies to save our lives and the lives of our loved ones.

While government plays a vital role in managing the response to the COVID-19 pandemic, its the private sector that will provide the solutions to identify and fight the disease. Who would you rather depend on profit-making private companies or bureaucratic government agencies?

The CDC response

In the United States, the Centers for Disease Control, a federal agency, was initially tasked with providing tests for COVID-19. Its test kits could not detect the difference between COVID-19 and lab-grade water.

The CDC also limited testing to patients who had recently traveled to China and were symptomatic. Whoops!

The lack of reliable test kits enabled the disease to spread throughout the United States. The U.S. Food and Drug Administration determined on Feb. 29 that certified labs, including commercial lab testing companies, could develop and distribute COVID-19 test kits.

Private companies and clinics stepped up quickly. Some examples:

The Cleveland Clinic developed an eight-hour test kit.

Hackensack Meridian Health developed a rapid response test kit that can provide results within a few hours.

On March 23, Everlywell became the first company to offer a test kit that consumers can use at home.

Roche shipped 400,000 test kits to labs across the United States beginning March 13, and an additional 400,000 the following week.

Thermo Fisher Scientific developed a test kit that can detect COVID-19 within four hours.

Drug companies in the United States and throughout the world are also working to develop a vaccine to fight COVID-19.

Cambridge-based Moderna Inc. has already begun Phase 1 testing of its mRNA-1273 vaccine that is based on the genetic sequence of COVID-19. Regeneron Pharmaceuticals of Tarrytown, New York, is working on an antibody treatment that uses the virus to build up antibodies that fight COVID-19. Inovio Pharmaceuticals of Plymouth Meeting, Pennsylvania., is developing INO-4800, a vaccine similar to Modernas that is made from optimized DNA plasmids.

But thats just a sample. At least 16 U.S. pharmaceutical companies are working on vaccines for COVID-19.

The government has been doing its part. President Trump declared a national emergency and Congress has been negotiating a massive spending bill, while the Federal Reserve Board dropped interest rates back to zero, resumed bond buying and provided liquidity to the banking system. None of these actions reassured investors and stopped the stock market from tanking. Recall that during the financial crisis, the Obama Administration invested more than $800 billion in a stimulus that stimulated the federal debt, but not the economy.

Communism vs. capitalism

While the government and private sector have both been working hard to battle the coronavirus, the Chinese government has been working hard to preserve the Communist Party by blaming the United States for the pandemic.

When Wuhan doctor Li Wenliang warned his colleagues in late December about a possible coronavirus that resembled SARS, local police reprimanded him for spreading rumors and he was called before a disciplinary council of the local Communist Party and forced to repent and confess, in writing, that he had spread rumors harmful to the glory of the Party, according to City Journal.

In early January, news of the virus started circulating on Chinese social media accounts. The government responded by shutting them down. By silencing news about the outbreak of COVID-19, Communist leaders allowed it to spread, resulting in the pandemic and thousands of deaths that could have been avoided.

Xu Zhiyong, an activist who criticized Chinese President Xi Jinpings response to the coronavirus, was jailed for subversion. Journalists Li Xehua, Fang Bin and Chen Qiushi, who tried to inform the public about the coronavirus outbreak, are all missing. And Western journalists who brought these stories to the worlds attention have been expelled from China.

Wuhan activists, professors and lawyers who had asked for President Xis resignation have all virtually disappeared. In addition to stifling the news at home, Chinas leaders failed to inform other countries about the severity of the coronavirus or to prevent its spread outside of China.

Should China be paying reparations to the rest of the world? Should it at least admit its guilt and apologize? According to an editorial in state-run media agency Xinhua, We should say righteously that the U.S. owes China an apology, the world owes China a thank you.

In addition, while the United States has shipped medical supplies to China to help fight the outbreak, China is threatening to impose export controls on pharmaceuticals needed by the U.S. to fight COVID-19.

In an article in Xinhua, Beijing bragged about its handling of COVID-19, according to Fox News. The article also claimed that China could impose pharmaceutical export controls which would plunge America into the mighty sea of coronavirus.

Without disclosing which drug or drugs are in short supply, the U.S. Food and Drug Administration announced a shortage of raw materials made in China that are needed to produce the drug.

While the United States is the world leader in medical research, China supplies 80% to 90% of antibiotics used in the United States, 70% of acetaminophen and about 40% of heparin, according to Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations.

Government vs. private sector

In other countries where health care is socialized, such as Italy and the United Kingdom, government responses have been underwhelming and politically charged.

Some 4,032 have died in Italy, more than in China, with 627 Italian deaths reported Friday (March 20) the highest daily toll for any country so far, according to The Wall Street Journal.

Which brings us back to the United States, where many Americans believe we would be better off with a socialized healthcare system. After all, many other countries have socialized medicine.

Some believe we should have price controls on drugs. Others believe that drug companies should not make profits and should make life-saving drugs available at no cost.

That belief would lead to no more life-savings drugs being developed, because there would be no incentive for companies to do so. Even if companies wanted to be able to give away free drugs, doing so would quickly put them out of business. Jobs would be eliminated and their stock would become worthless.

The average cost to develop a new drug is $2.6 billion. Post-approval research and development costs, such as the cost of monitoring effectiveness and safety, average $312 million and boost the total cost for each approved drug to almost $3 billion.

Most drugs never make it to market. Only about 12% of drugs that enter clinical testing are eventually approved for public use.

Some drug companies have made a great deal of money. Some have taken advantage of the drug-approval process and charged outrageous prices for their products.

Weve all heard about companies like Theranos, which achieved a valuation of $9 billion based on fraudulent blood-testing technology, or Mylans price gouging for its EpiPen. Companies in any industry that take advantage of their customers usually pay in the end, but in such cases, government involvement is necessary.

Regardless, even with no vaccine yet available, special interest groups that pretend that their interest is our interest are calling for President Trump to prohibit profiteering by Big Pharma during the coronavirus pandemic.

If Big Pharma develops a vaccine that works, the company that does so should make a significant profit. Is there a sector more deserving of a profit than one that saves lives? While small businesses are suffering most during the pandemic, large companies have also had to deal with major losses, a huge drop in their stock price and mounting expenses in an attempt to staunch the bleeding.

In 1900, 37% of all American deaths were from infectious diseases, George Will wrote. Today the figure is 2%.

Id rather the drug companies get a cut of my hard-earned money than the more than 70 groups that are trying to stop them from earning a profit. To my knowledge, none of the 70 groups has criticized President Xi.

Brenda P. Wenning of Newton is president of Wenning Investments LLC in Newton. She can be reached at Brenda@WenningInvestments.com or 617-965-0680. For additional information, visit her blog at http://www.WenningAdvice.com.

Link:
Drug companies are the good guys - MetroWest Daily News

Read More...

Nobel laureate Luc Montagnier inaccurately claims that the novel coronavirus is man-made and contains genetic material from HIV – Health Feedback

Monday, April 27th, 2020

CLAIM

"this coronavirus genome contained sequences of another virus [] the HIV virus (AIDS virus)"

DETAILS

Inaccurate: Genomic analyses indicate that the virus has a natural origin, and was not engineered. The so-called unique protein sequence insertions found in the 2019 novel coronavirus can be found in many other organisms, not just HIV.

KEY TAKE AWAY

Genomic analyses of the novel coronavirus show that it was not engineered. In addition, the claim that its genome contains inserted HIV sequences is based on a now-withdrawn preprint of a study that contained significant flaws in design and execution. The so-called HIV insertions identified by the authors are in fact gene sequences that can also be found in many other organisms besides HIV.

REVIEW Numerous articles published in April 2020 report that Nobel laureate Luc Montagnier claimed that SARS-CoV-2 is a manipulated virus that was accidentally released from a laboratory in Wuhan, China and that Indian researchers have already tried to publish the results of the analyses that showed that this coronavirus genome contained sequences of another virus [] the HIV virus (AIDS virus). The claim that SARS-CoV-2 contains HIV insertions began circulating in January 2020, and was propagated by outlets such as Zero Hedge and Infowars. Health Feedback covered this claim in early February 2020, and found it to be inaccurate.

Firstly, genomic analysis of the novel coronavirus, published in Nature Medicine, has demonstrated that the virus is not the product of bioengineering, but is rather of natural origin[1]. The current most likely theory, based on what scientists know about viral evolution, is that the virus first emerged in pangolins or bats (or both) and later developed the ability to infect humans. This ability to infect human cells is conferred by the so-called spike (S) protein, which is located on the surface of the enveloping membrane of SARS-CoV-2.

After the 2003-2005 SARS outbreak, researchers identified a set of key amino acids within the S protein which give SARS-CoV-1 a super-affinity for the ACE2 target receptor located on the surface of human cells[2,3]. Surprisingly, the S protein of the current SARS-CoV-2 does not contain this optimal set of amino acids[1], yet is nonetheless able to bind ACE2 with a greater affinity than SARS-CoV-1[4]. This finding suggests that SARS-CoV-2 evolved independently and undermines the claim that it was manmade[1]. Indeed, the best engineering strategy would have been to harness the known and efficient amino acid sequences already described in SARS-CoV-1 order to produce a more optimal molecular design for SARS-CoV-2. The authors of the Nature Medicine study[1] concluded that Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.

Secondly, the claim that SARS-CoV-2 contains HIV insertions is based on a preprint of a research study uploaded to bioRxiv on 2 February 2020. A preprint is a study in progress that has not been peer-reviewed by other scientists. The authors of the preprint, titled Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag, claimed to have found 4 insertions in the spike glycoprotein (S) which are unique to 2019-nCoV and are not present in other coronaviruses. The authors further asserted that all of [these inserts] have identity/similarity to amino acids residues in key structural proteins of HIV-1 [which] is unlikely to be fortuitous in nature.

The work was swiftly criticized by experts. In this Forbes article, Arinjay Banerjee, a postdoctoral fellow at McMaster University who has studied coronaviruses, said that:

The authors compared very short regions of proteins in the novel coronavirus and concluded that the small segments of proteins were similar to segments in HIV proteins. Comparing very short segments can often generate false positives and it is difficult to make these conclusions using small protein segments.

Researchers also took to Twitter to demonstrate this problem first-hand. Trevor Bedford, a faculty member at the Fred Hutchinson Cancer Research Center who studies viral evolution, re-analyzed the gene and protein sequences used by the authors and found that the so-called unique inserts appeared in many other organisms, including Cryptosporidium and Plasmodium malariae, which cause cryptosporidiosis and malaria, respectively.

Assistant professor at Stanford University Silvana Konermann also checked the authors findings and came to the same conclusion, calling the similarity spurious.

This has also been independently confirmed in another published analysis[5]. In other words, these sequences are not insertions, but are rather common sequences found in numerous other organisms such as bacteria and parasites. Therefore, the existence of these sequences in SARS-CoV-2 does not provide evidence of a link to HIV, nor that scientists purposely inserted HIV sequences into the SARS-CoV-2 genome.

In summary, genomic analysis of the virus indicates that it does not contain so-called HIV insertions and that it was not engineered in a lab. Evidence points to the virus having a natural origin.

The only thing accurate about these articles is that Nobel Prize winner and virologist Luc Montagnier did in fact make these claims. Although he holds impressive scientific credentials, his claims run contrary to credible scientific evidence. And despite having won the Nobel Prize in Physiology or Medicine in 2008 for his co-discovery of the link between HIV and AIDS, Montagnier now promotes widely discredited theories such as the pseudoscience of homeopathy and that autism is caused by bacteria that emit electromagnetic waves. Articles which repeat Montagniers claims without critically evaluating their veracity exhibit the common appeal to authority fallacy, in which something is assumed to be true simply because the person saying it is considered to be an expert, thereby misleading readers into believing that this theory is scientifically credible. This demonstrates the importance of verifying scientific claims with other experts in the same field, rather than simply taking such claims from a single expert at face value.

SCIENTISTS FEEDBACK [These comments come from an evaluation of a related claim.] Aaron T. Irving, Senior Research Fellow, Duke-NUS Medical School:Its easier to believe misinformation when it is mixed with truth. The region highlighted in the pre-print is indeed an insertion in nCoV-2019 relative to its bat ancestors and indeed it has high identity to the HIV gp120/gag. However, the authors chose to align only this small region and not do a basic check on whether there were other sequences which were also homologous (showing high degree of similarity/identity). As it turned out, the region is also homologous to many unrelated sequences. As such, the conclusions drawn from the data are no longer valid and there are many open-ended questions regarding this region highlighted. I see the authors themselves agree with this criticism by other scientists and have voluntarily withdrawn their preprint pending a much deeper investigation.

The author of this article by European Scientist also compared the genome sequences of SARS-CoV-2 and HIV using the Basic Local Alignment Search Tool (BLAST), developed by the U.S. National Institutes of Health, and found no significant similarity, explaining that In plain English, SARS-CoV-2 is not made of the bat coronavirus and small bits of the HIV virus. Readers who wish to verify the level of sequence identity between the two viruses for themselves are welcome to follow the steps listed in the article.

Here is the original post:
Nobel laureate Luc Montagnier inaccurately claims that the novel coronavirus is man-made and contains genetic material from HIV - Health Feedback

Read More...

Team spirit – THE WEEK

Monday, April 27th, 2020

So when does the world get back to normal? It is a question that is on the mind of half of the worlds 7.8 billion people who have been asked to stay put at home to avoid a virus that has made millions sick. Not until a good vaccine is developed, Dr Anthony Fauci, Americas top infectious diseases expert, told reporters recently at a White House press briefing.

In normal times, experts say developing an effective vaccine would take anywhere between five and 10 years. But these are unprecedented times, and even scientists are being compelled to find newer ways to develop and test vaccines. Best-case scenarios for vaccine development have already shrunk the time frame to 12 to 18 months; globally, more than 100 vaccine candidates are at different stages of development. Five of these have reached the Phase 1 trials, and 18 are in pre-clinical stage, said Dr Shahid Jameel, virologist and CEO, Wellcome Trust/DBT India Alliance.

Closer home, Indian scientists, researchers and vaccine manufacturers are racing ahead, after Prime Minister Narendra Modi, in his speech on April 14, asked Indias young scientists and researchers to come forward to work on a vaccine against Covid-19.

For those working on vaccines, what has helped, said Premas Biotech cofounder and managing director Prabuddha Kundu, is that regulatory pathways are being fast-tracked and regulators are now willing to consider new scientific processes, and collaborations are happening.

Bharat Biotech is collaborating with virologists at the University of Wisconsin-Madison and vaccine company FluGen on a unique intranasal vaccine called CoroFlu.

For a country that is a leading manufacturer and supplier of vaccines, India definitely has some advantages in building one. According to the department of biotechnology, the government body that is leading the hunt for the vaccine development, four major companiesSerum Institute of India, Zydus Cadila, Bharat Biotech, Biological E Ltdhave a candidate each, besides academic research groups from the Indian Institute of Science, International Centre for Genetic Engineering and Biotechnology, National Institute of Immunology, and Translational Health Science and Technology Institute.

Vaccines are built by taking different approaches, said Jameel. They can either use inactivated viruses (for instance, the injectable polio vaccine); or live attenuated or weakened virus (the oral polio vaccine built in the 1950s) that is weakened to the point that it infects and multiplies, but does not cause disease; or subunit vaccines, where you take a part of the virus (protein), produce en masse and purify it and use it as a vaccine. The idea is to choose the antigens that best stimulate the immune system. One method of production involves isolating the specific protein from the virus or producing it using recombinant DNA technology and then administering it on its own. This reduces the likelihood of adverse reactions to the vaccine. The hepatitis-B vaccine is one example of that approach, said Jameel. Besides, vaccines being developed are also either based on DNA, RNA, or vector vaccine-based approaches.

The selection of an antigen and the antigenic design of the potential candidate will have a profound effect in generating an effective immune response. Since spike protein of the SARS-CoV-2 is a potential target, one will need to decide whether full-length spike glycoprotein or part of the protein that binds with the receptor needs to be selected, said Professor Sunit K. Singh, head, molecular biology unit, faculty of medicine, Institute of Medical Sciences, Banaras Hindu University.

For now, Premas Biotech seems to have worked around some of those issues. The Gurugram-based company, in collaboration with US-based Akers Biosciences, is working on its vaccine candidate using a mixture of three antigens produced in bakers yeast. Its cofounder and managing director, Prabuddha Kundu, said that traditionally vaccines were made by injecting heat-killed or attenuated whole viruses or bacteria, but since that had side effects, the approach of late has been to take a part of surface proteins, purify and produce it recombinantly (by rearranging genetic material) to elicit an antibody response.

In the case of SARS-CoV-2, one of the top targets is the spike protein present on the outer surface of the virus, and is understood to be the weapon with which it binds to the human cells (receptors) and gains entry. But since there were concerns about mutations in spike proteins, Kundu said that his team had created a mixture of the spike protein and two other proteins found on the outer membrane of the virus. These, said Kundu, would be replicated on its genetically engineered platform of bakers yeast (D-CryptTM). The platform has worked in the past, tooit has been successful in expressing 30 proteins similar to those in the structure of the selected Covid-19 antigens. It is also safer, and cost-effective, said Kundu, adding that the company has applied for animal trials with the Review Committee on Genetic Manipulation.

In Hyderabad, Bharat Biotech is collaborating with virologists at the University of Wisconsin (UW)-Madison and vaccine company FluGen on a unique intranasal vaccine called CoroFlu. The new vaccine is being built on the backbone of the trios flu vaccine candidate known as M2SR, developed a couple of years ago. M2SR is a self-limiting version of the influenza virus that induces an immune response against the flu, said Dr Krishna Ella, chairman and managing director, Bharat Biotech. [FluGen cofounder Yoshihiro] Kawaokas lab will insert gene sequences from SARS-CoV-2 into M2SR so that the new vaccine will also induce immunity against the novel coronavirus.

CoroFlus safety and efficacy in animal models is being assessed at the UW-Madisons influenza research institute, said Ella, which could take four to six months. Post the results of animal trials, which is crucial, Bharat Biotech will begin production scale-up for safety and efficacy testing in humans. CoroFlu could be in human clinical trials by the fall of 2020, he said.

Bharat Biotech is also working on a second candidate that will utilise the inactivated rabies vector platform, for which funding has been approved by the department of biotechnology. The department has also recommended funding support to Ahmedabad-based Zydus Cadila for advancing the development of a DNA vaccine candidate, as well as Phase 3 human clinical trials for recombinant BCG vaccine (VPM1002) planned in high-risk population by the Pune-based Serum Institute of India (SII). SII is also testing its vaccine candidate (in collaboration with US-based biotech company Codagenix) on the animal models and hopes to have a vaccine by 2021, its CEO Adar Poonawalla has said.

Despite the urgency, there are challenges in making a vaccine for SARS-CoV-2, said Kundu. The tools that are normally available to us otherwise are not available here, he said. For instance, they did not have specific antibodies to test antigens. Despite that we have been able to work through this by developing surrogate models, he said.

The amount of time that the immunity lasts in the body is also something that is still not known. In the case of SARS-CoV and MERS infections, the natural immunity does not last long, said Singh. Based on that knowledge, one has to also decide the doses of vaccination to be given in order to have immunity for a long time. The challenge to produce in huge quantities to cover the population under a mass vaccination programme will also need to be taken on. That will require a global coalition, and not just a few companies.

For those working on vaccines, what has helped, said Kundu, is that regulatory pathways are being fast-tracked and regulators are now willing to consider new scientific processes, and collaborations are happening. For instance, two global vaccine manufacturersSanofi and GSKhave come together to develop an adjuvant vaccine for Covid-19. Sanofi is providing the antigen that will be produced on its Baculovirus Expression Vector System platform, said its spokesperson. The recombinant technology produces an exact genetic match to proteins found on the surface of the virus, the spokesperson told THE WEEK. GSK will provide its novel adjuvant technologyAS03.

An adjuvant is a substance that is combined with a vaccine antigen to help stimulate a stronger and more targeted immune response. This can help provide better protection or in some instances, like a pandemic, could reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and supplied, said the spokesperson. This is a critical advantage in a pandemic setting. The AS03 adjuvant will help improve the immune response to the antigen and may also be antigen sparing. Due to the critical need for a vaccine to address Covid-19, Sanofi will be testing its own adjuvant as well.

According to Jameel, the challenge in building a vaccine against Covid-19 may not be any different from making a vaccine for other diseases. The power of technology available today is evident from the fact that since the pandemic began in January, we already have more than 100 candidates, he said. For India, the opportunity will be in manufacturing the vaccines that are developed eventually and making them affordable for all.

More here:
Team spirit - THE WEEK

Read More...

UCLA scientists invent nanoparticle that could improve treatment for bone defects – UCLA Newsroom

Monday, April 27th, 2020

In test with mice, the sterosome activated bone regeneration was activated without needing additional drugs

Microscopic image showing the interaction between nanoparticles (green) loaded with therapeutic drugs (red), and cells (blue) on a tissue engineering scaffold.

A team of biomaterials scientists and dentists at the UCLA School of Dentistry has developed a nanoparticle that, based on initial experiments in animals, could improve treatment for bone defects.

A paper describing the advance is published today in the journal Science Advances.

Bone defects, which can be caused by traumatic injury, infection, osteoporosis or the removal of tumors, are difficult for orthopedic surgeons to treat. And the need for bone grafts are becoming more common thanks in part to our aging population: Bone injuries are particularly prevalent among the elderly.

Today, the standard treatment for bone defects is a bone graft, which involves transplanting healthy bone from another part of the body to repair the damaged area. However, the procedure can cause complications, including infections where the transplanted bone is taken from, bleeding and nerve damage.

So the researchers turned their attention to liposomes, tiny spherical sacs that are derived from naturally existing lipids. Liposomes have been used since the 1990s to treat cancer and infectious diseases, and more recently they are being explored for their possible use in bone tissue engineering. They can be used to administer nutrients and pharmaceutical drugs in the body and can easily enter cells to administer their valuable cargo, but they do have some drawbacks: They are physically unstable and it can be difficult to control how and when they release drugs.

To help improve their stability and enhance their ability to form bone in the body, the UCLA researchers developed a new type of liposome called a sterosome. (The name is inspired by the fact that they contain a high concentration of steroids.)

To produce the sterosomes, the scientists replaced cholesterol, an important component of liposomes, with oxysterol, a type of cholesterol that has a key role in skeletal development and bone healing. In tests using mice with bone defects, the researchers found that the sterosomes successfully activated bone regeneration on their own, without needing therapeutic drugs.

Liposomes are generally made from pharmacologically inactive substances, said Min Lee, the papers corresponding author and a professor of biomaterials science at the dental school. Including oxysterol into our liposomal formulation not only increased nanoparticle stability but also stimulated cells to develop into bone-forming cells.

In a second phase of the study, the researchers wanted to see how they could make the sterosome even more effective.

They added their sterosome nanoparticle to a tissue engineering scaffold a structure often used to move and grow naturally occurring stem cells, which is matched to the site of the defect and is used during bone graft procedures. They loaded the sterosomes with a bone-building drug called purmorphamine. Next, they immobilized the drug-loaded sterosome onto a scaffold to ensure that the sterosomes stayed concentrated in the defective areas and released the drugs where they were most needed for as long as possible.

In a six-week study using mice with bone defects in their skulls, the researchers saw an average reduction of roughly 50% in the size of the defects after the drug-loaded scaffold was implanted.

By using our nanoparticle, which we found has intrinsic bone-forming capabilities, along with the addition of therapeutic drugs, we were able to speed up the bone regeneration process, Lee said. Our nanoparticle-packaged drugs will be useful in many clinical situations where bone grafting is required to treat non-healing skeletal defects and related bone pathologies.

Dr. Paul H. Krebsbach, professor of periodontics and dean of the dental school, said,The research led by Min Lee and his team demonstrates that UCLA Dentistrys research endeavors go well beyond treating the diseases of the oral cavity, and their findings have wider implications for treating bone defects throughout the entire body.

The studys other authors are Chung-Sung Lee, Soyon Kim, Jiabing Fan, Hee Sook Hwang and Dr. Tara Aghaloo, all of UCLA.

The study was funded by the National Institute of Dental and Craniofacial Research, the U.S. Department of Defense and Musculoskeletal Transplant Foundation Biologics. The authors report no conflicts of interest.

Read more:
UCLA scientists invent nanoparticle that could improve treatment for bone defects - UCLA Newsroom

Read More...

What comic book super heroes and villains tell us about plant and human gene editing and the coronavirus – Genetic Literacy Project

Sunday, April 26th, 2020

Humanity is currently facing a huge challenge imposed by the coronavirus. Borders are being shut down, planes grounded, and factories closed. At the same time, scientists and public health professionals are working on tests, treatments, and vaccines to soon provide a medical response. Coping with corona might be one of the largest tests humans have faced in the past decades but it wont be the last virus we need to defeat. It is time to embrace bioscience and allow more research and applications of genetic alteration methods.

For the layman, all this technobabble about mutagenesis and genetic engineering is difficult to comprehend and it took me personally a good amount of reading to start grasping what different methods exist and how these can massively improve our quality of life.

Lets first look at the four most common ways to alter the genes of a plant or animal:

This can be even done in grown humans that are alive, which is a blessing for everyone who suffers from genetic disorders. We are able to repair genes in live organisms. Gene editing is also thousands of times more accurate than just bombarding seeds with radiation. Some applied examples are deactivating the gene responsible for generating gluten in wheat: The result is gluten-free wheat. There are several methods that achieve this. One of the most popular ones these days is the so-called CRISPR Cas-9. These scissors are usually reprogrammed bacteria that transmit the new gene information or deactivate defunct or unwanted genes. Many science fiction novels and movies show a future in which we can deactivate genetic defects and cure humans from terrible diseases. Some examples of stories in which CRISPR-like techniques have been used are movies such as GATTACA, Star Treks Wrath of Khan, or the Expanse series in which gene editing plays a crucial role in growing crops in space.

Synthetic biologists have started usingCRISPR to synthetically create partsof the coronavirus in an attempt to launch a vaccine against this lung disease and be able to mass-produce it very quickly. In combination with computer simulations and artificial intelligence, the best design for such a vaccine is calculated on a computer and then synthetically created. This speeds up vaccine development and cuts it from years to merely months. Regulators and approval bodies have shown that in times of crisis they can also rapidly approve new testing and vaccination procedures which usually require years of back and forth with agencies such as the FDA?

CRISPR also allows the search for specific genes, also genes of a virus. This helped researchersto build fast and simple testing proceduresto test patients for corona.

In the long term, gene editing might allow us to increase the immunity of humans by altering our genes and making us more resistant to viruses and bacteria.

While the coronavirus seems to really test our modern society, we also need to be aware that this wont be the last pathogen that has the potential to kill millions. If we are unlucky, corona might mutate quickly and become harder to fight. The next dangerous virus, fungus, or bacteria is probably around the corner. Hence we need to embrace the latest inventions of biotechnology and not block genetic research and the deployment of its findings.

Right now a lot of red tape and even outright bans are standing between lifesaving innovations such as CRISPR and patients around the world. We need to rethink our hostility towards genetic engineering and embrace it. To be frank: We are in a constant struggle to fight newly occurring diseases and need to be able to deploy state of the art human answers to this.

Fred Roeder is a Health Economist from Germany and has worked in healthcare reform in North America, Europe, and several former Soviet Republics. One of his passions is to analyze how disruptive industries and technologies allow consumers more choice at a lower cost. Follow him on Twitter @FredCyrusRoeder

A version of this article was originally published at Consumer Choice Center and has been republished here with permission. The center can be found on Twitter @ConsumerChoiceC

See original here:
What comic book super heroes and villains tell us about plant and human gene editing and the coronavirus - Genetic Literacy Project

Read More...

Coronavirus might be changing into less infective form, DU teacher’s research finds – Dhaka Tribune

Sunday, April 26th, 2020

GGG>AAC changes in the SARS-CoV-2 have resulted in two types of strains with different infectivity as shown in the research of Dr. Mustak Ibn Ayub. These two strains can be further subdivided which helps to understand both infectivity and lethality of SARS-CoV-2 in different regions Courtesy

The observation sheds light on the association between Sars-CoV-2 mutations and its infectivity for the first time

Sars-CoV-2, the new strain of coronavirus behind the global Covid-19 pandemic, has changed in different countries by accumulating only a handful of key changes in its genome. Among them, a unique change has made the virus less infective, according to a research.

Dr Mustak Ibn Ayub, assistant professor at the department of genetic engineering and biotechnology at Dhaka University, discovered the unique change during his research of the virus' genetic mutations, according to a press statement.

A genome is the complete genetic information of any living entity that works as the blue print to determine its characteristics.

Dr Mustak, who obtained his PhD from Oxford University in the UK, characterized two strains of the virus after analyzing 3,000 complete genome sequences of Sars-CoV-2.

Designated as Sars-CoV-2a and Sars-CoV-2g, the strains have a unique difference in the 28,881-28,883 position of their genomes.

In Sars-CoV2g, those three positions are occupied by GGG, but in Sars-CoV2a, the GGG positions have mutated into AAC, the research findings show.

This is a unique event where three nucleotide (the building blocks of the virus genome) have changed as a bloc among 30,000 such positions in the virus genome.

Dr Mustak Ibn Ayub | CourtesyThe research also showed that this unique mutation negatively affects the nucleocapsid (N) protein, a crucial component for virus multiplication and infection of new cells.

The journal paper written based on the research is waiting peer review but has been published as a preprint here.

A remarkable finding in Dr Mustaks research is that the Sars-CoV-2a strain is prevalent in areas or countries with relatively low Covid-19 cases, such as Portugal, Netherlands, and Belgium, whereas in highly affected countries such as the US, Spain, France, and Germany, Sars-CoV-2g is predominant.

This trend is also true in different regions within a country, as shown in the research; Abruzzo in Italy has very low Covid-19 cases and high presence of Sars-CoV-2a.

This crucial observation sheds light on the association between Sars-CoV-2 mutations and its infectivity for the first time.

However, Dr Mustak cautioned that more studies need to be designed and executed on this aspect of Sars-CoV-2 mutation across the world.

He expects that from such research, monitoring the dynamics of these two strains will give valuable information to understand and manage the course of Covid-19 pandemic around the globe.

Read more here:
Coronavirus might be changing into less infective form, DU teacher's research finds - Dhaka Tribune

Read More...

Did the COVID-19 virus originate from a lab or nature? Examining the evidence for different hypotheses of the novel coronavirus’ origins – Health…

Sunday, April 26th, 2020

Since the beginning of the COVID-19 outbreak in December 2019, many hypotheses have been advanced to explain where the novel coronavirus (SARS-CoV-2) actually came from. Initial reports pointed to the Huanan seafood market in Wuhan, China, as the source of infection, however later studies called this into question. Given the uncertainty, many have suggested that a laboratory in Wuhan may be the actual source of the novel coronavirus. In this Insight article, we examine the three most widespread origin stories for the novel coronavirus, and examine the evidence for or against each proposed hypothesis. The hypotheses are listed in order from least likely to most likely, based on currently available evidence.

Although none of the individual pieces of evidence described below definitively identify the virus origin, the preponderance of evidence when taken together currently points to a natural origin with a subsequent zoonotic transmission from animals to humans, rather than a bioengineering or lab leak origin.

Hypothesis 1: The novel coronavirus is manmade, genetically engineered as bioweaponry or for health applications This hypothesis began circulating in February 2020. To date, it has been largely rejected by the scientific community. Some of the early claims have their roots in a preprint (a study in progress which has not been peer-reviewed or formally published) uploaded to ResearchGate by Chinese scientists Botao Xiao and Lei Xiao, who claimed that somebody was entangled with the evolution of 2019-nCoV coronavirus. In addition to origins of natural recombination and intermediate host, the killer coronavirus probably originated from a laboratory in Wuhan.

However, the only piece of evidence the authors provided to support their conclusion was the proximity of both the Wuhan Centers for Disease Control & Prevention and the Wuhan Institute of Virology (WIV) to the seafood market. The authors later withdrew their article, saying that their speculation about the possible origins was not supported by direct proofs. Copies of the original article can still be found online.

The withdrawal of the preprint did not stop this hypothesis from spreadinginstead it continued to grow in complexity, with some claiming that the virus showed signs of genetic engineering. Some of these claims were based on a preprint uploaded to BioRxiv, purporting to show that genetic material from the human immunodeficiency virus (HIV) had been inserted into the novel coronavirus.

This study was found to have significant flaws in design and execution and was also later withdrawn, as reported in our review explaining that No, HIV insertions were not identified in the 2019 coronavirus. However, the poor quality of the preprint did not prevent this baseless speculation from being promoted by blogs such as Zero Hedge, Infowars, Natural News, and even some scientists like Luc Montagnier, a French virologist who co-discovered HIV, but has recently become a promoter of numerous unsupported theories.

Indeed, scientists who examined the preprint highlighted that these so-called insertions are very short genetic sequences which are also present in many other life forms, such as the bacterium Magnetospirillum magnetotacticum, the spider Araneus ventricosus, and the parasites Cryptosporidium and Plasmodium malariae, which cause cryptosporidiosis and malaria, respectively[1,2]. Trevor Bedford, virologist at Fred Hutchinson Cancer Research Center and professor at the University of Washington, explained on Twitter that a simple BLAST of such short sequences shows [a] match to a huge variety of organisms. No reason to conclude HIV. [] These inserts are nothing of the sort proposed by the paper and instead arose naturally in the ancestral bat virus.

In other words, the sequences analyzed by the study authors were so short that it is easy to find similarities to a wide variety of organisms, including HIV. An analogy would be to search for a short and commonly-used word, like sky, in a search engine and claim that the search results show content that is identical or similar to each other solely because of that one word.

Another version of the engineered-virus story stated that a pShuttle-SN sequence is present in the novel coronavirus. The pShuttle-SN vector was used during efforts to develop candidates for a SARS vaccine[3] and was therefore used to support claims of human engineering. These claims appeared in blogs such as Infowars, Natural News, and The Epoch Times. However, analysis of the genomic sequence of the novel coronavirus showed that no such man-made sequence was present, as reported in our review.

Other claims regarding the purported manmade origins of the virus have linked it to bioweapons research. These have appeared in articles such as a 22 February 2020 story by the New York Post, which we also reviewed and scientists found to be of low scientific credibility. The article provided no evidence that the novel coronavirus is linked to bioweapons research.

On 17 March 2020, a group of scientists published findings from a genomic analysis of the novel coronavirus in Nature Medicine[4], which established that SARS-CoV-2 is of natural origin, likely originating in pangolins or bats (or both) and later developing the ability to infect humans. Their investigation focused mainly on the so-called spike (S) protein, which is located on the surface of the enveloping membrane of SARS-CoV-2. The S protein allows the virus to bind to and infect animal cells. After the 2003-2005 SARS outbreak, researchers identified a set of key amino acids within the S protein which give SARS-CoV-1 a super-affinity for the ACE2 target receptor located on the surface of human cells[5,6].

Surprisingly, the S protein of SARS-CoV-2 does not contain this optimal set of amino acids[4], yet is nonetheless able to bind ACE2 with a greater affinity than SARS-CoV-1[7]. Taken together, these findings strongly suggest that SARS-CoV-2 evolved independently of human intervention and undermine the claim that it was manmade[1]. This is because if scientists had attempted to engineer improved ACE2 binding in a coronavirus, the best strategy would have been to harness the already-known and efficient amino acid sequences described in SARS-CoV-1 in order to produce a more optimal molecular design for SARS-CoV-2. The authors of the Nature Medicine study[4] concluded that Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.

In summary, the hypothesis that the virus is manmade or engineered in any way is unsupported and inconsistent with available evidence, leading Bedford to assess the probability of this hypothesis being correct as extremely unlikely. Kristian Andersen, professor at the Scripps in San Diego declared during an online seminar, I know there has been a lot of talk about Chinese bioweapons, bioengineering, and engineering in general. All of that, I can say, is fully inconsistent with the data.

Like Andersen, other scientists have repeatedly explained that there is no evidence to support the claim that the virus was human engineered. In a statement published on 19 February in The Lancet, 27 eminent public health scientists in the U.S., Europe, the U.K., Australia, and Asia cited numerous studies from multiple countries which overwhelmingly conclude that this coronavirus originated in wildlife[8-15] as have so many other emerging pathogens.

[Back to top]

Hypothesis 2: The novel coronavirus is a natural virus that was being studied in the lab, from which it was accidentally or deliberately released Many have pointed out that even though the virus was unlikely engineered, it still might have been purposely or accidentally released from a lab. Claims about a possible laboratory release often point to a laboratory in China as the source, more specifically the Wuhan Institute of Virology (WIV), given that one of its laboratories studies bat coronaviruses. Similarly speculative claims have also implicated laboratories in the U.S. and Canada.

However, there is no evidence in either scientific publications or public announcements indicating that a virus resembling SARS-CoV-2 had been studied or cultured in any lab prior to the outbreak. While this of course does not rule out the possibility that scientists were working on it in secret, as of today, this claim is speculative and unsupported by evidence.

A January 2020 study in The Lancet, which found that about one-third of the initial round of infections had no connection to the Huanan seafood market[15], has been suggested as evidence that the virus may have leaked from a nearby lab. Richard Ebright, a professor of chemical biology at Rutgers, said in this CNN article:

It is absolutely clear the market had no connection with the origin of the outbreak virus, and, instead, only was involved in amplification of an outbreak that had started elsewhere in Wuhan almost a full month earlier.

Ebright also told CNN that The possibility that the virus entered humans through a laboratory accident cannot and should not be dismissed.

Nikolai Petrovsky, a professor at Flinders University who specializes in vaccine development, also supported the hypothesis that the virus could have escaped from a lab. In this article, he stated that no corresponding virus has been found to exist in nature and cited as-yet unpublished work, saying that the hypothesis is absolutely plausible. Petrovsky suggested that the virus could have escaped [the biosecure facility in Wuhan] either through accidental infection of a staff member who then visited the fish market several blocks away and there infected others, or by inappropriate disposal of waste from the facility that either infected humans outside the facility directly or via a susceptible vector such as a stray cat that then frequented the market and resulted in transmission there to humans.

Some have argued that instead of originating in nature, the virus could have been generated through simulated evolution in the lab. Christian Stevens, from the Benhur Lee lab at the Mount Sinai School of Medicine, explained in this article the extreme unlikelihood of this scenario.

Briefly, the mutations in the receptor-binding domain (RBD) of the S protein in SARS-CoV-2 resembles that of some pangolin coronaviruses. These mutations are also what make SARS-CoV-2 much better at infecting humans compared to SARS-CoV-1. Such mutations could be evolved in the lab through simulated evolution, however the likelihood of simulated natural selection stumbling on the near exact RBD from a previously unknown pangolin coronavirus is mathematically unlikely, said Stevens.

Furthermore, scientists would have had to know about these mutations in the S protein of some pangolin coronaviruses before the outbreak, and then tried to evolve a bat coronavirus with the same characteristics through animal experiments. As these mutations in pangolin coronaviruses were not identified until after the outbreak[16], it does not make sense for scientists to have performed such experiments in the lab, as there would have been little to no scientific justification for doing so.

Other considerations are the polybasic cleavage site and the O-linked glycan additions to the S protein, which have not been identified in bat betacoronaviruses nor the pangolin betacoronaviruses sampled so far. However, evidence indicates that these features are much more likely to have arisen in the presence of an immune system, suggesting that this is a natural adaptation by the virus to a live host, either an animal or a human. Because lab-based cell cultures do not have immune systems, Stevens explained that it is extremely unlikely that the virus would have developed such features using cell culture approaches, thereby undermining the lab-generated claims that some have proposed.

What about using animal models for evolution, which would provide selective pressure from an immune system? Stevens also examined this possibility and explained that there is no known animal model that would allow for selection of human-like ACE2 binding and avoidance of immune recognition. This strongly suggests that SARS-CoV-2 could not have been developed in a lab, even by a system of simulated natural selection.

In other words, the overall combination of features observed in SARS-CoV-2 is extremely unlikely to have arisen through experiments, even simulated evolution, because the experimental tools are not available at the moment.

Zhengli Shi, the head of the laboratory studying bat coronaviruses at the WIV, clarified in a Scientific American report published on 11 March, that during the early days of the outbreak, she had her team check the genome sequence of SARS-CoV-2 against the bat coronavirus strains being studied in her lab to ensure that the outbreak had not resulted from any mishandling of experimental materials, especially during disposal. They found that none of the sequences matched those of the viruses her team had sampled from bat caves.

However, this testimony has not satisfied those who allege a cover-up of a lab accident due to inadequate biosecurity, intentional release, or plain carelessness. Recent opinion pieces published by the Washington Postone on 2 April 2020 and another on 14 April 2020have also fueled speculation that the virus was accidentally released from a laboratory at the WIV due to biosafety lapses reportedly documented in diplomatic cables from 2018. The authors of these opinion pieces were careful to distance themselves from earlier claims that the coronavirus was bioengineered or resulted from deliberate wrongdoing, as one author stated. In any event, the accidental release scenario is currently being considered by scientists and U.S. intelligence and national security officials.

Indeed, despite safeguards, laboratory accidents can and do occur, and some have even caused outbreaks. In 2007, an outbreak of hand-foot-mouth (HFM) disease among livestock in the U.K. was linked to a faulty gas valve connected to labs involved in researching and producing HFM vaccines. And in 2004, a re-emergence of SARS occurred in Beijing, China, as a result of two lab accidents.

In an article published on 6 April, experts expressed skepticism at the lab leak hypothesis. Vincent Racaniello, a professor of virology at Columbia University, said I think it has no credibility. And Simon Anthony, an assistant professor at Columbia who studies the ecology and evolution of viruses, stated, it all feels far-fetched [] Lab accidents do happen, we know that, but [] theres certainly no evidence to support that theory.

In an April 10th article, Amesh Adalja from Johns Hopkins University Center for Health Security stated that he thought the lab leak hypothesis had a lower probability than the pure zoonotic theory. I think as we get a better understanding of where the origin of this virus was, and get closer to patient zero, that will explain some of the mystery. Bill Hanage, associate professor at the Harvard T.H. Chan School of Public Health, said If there is evidence to really support this theory beyond the coincidence of the location of the lab, then I havent seen it, and I dont make decisions on the basis of coincidence.

Several scientists have taken to Twitter to ponder the lab leak hypothesis made by the Washington Post opinion articles:

Overall, we have virus group, molecular features, market association, and environmental samples all pointing strongly towards zoonosis. The location in Wuhan is the only thing at all suggestive of lab escape. I see strength of evidence entirely for zoonosis.

Trevor Bedford

We dont know how this virus emerged, but all evidence points to spillover from its natural reservoir, whether that be a bat or some other intermediate species, pangolins or otherwise. Pushing this unsupported accident theory hinders efforts to actually determine virus origin.

Angela Rasmussen

The bottom line is that those vague diplomatic cables do not provide any specific information suggesting that [SARS-CoV-2] emerged from incompetence or poor biosafety protocols or anything else.

Angela Rasmussen [referencing the 14 April Washington Post opinion piece]

Most likely either 1) virus evolved to its current pathogenic state via a non-human host and then jumped to humans, or 2) a non-pathogenic version of the virus jumped from an animal into humans then evolved to a pathogenic state.

Josh Michaud

All current data supports that the ancestral station strain of the virus is in batsthey serve as the zoonotic reservoir. Then a spillover event occured into humans, perhaps aided by another mammal, although thats debatable.

Ryan McNamara

There is strong evidence that the #SARSCoV2 #coronavirus is NOT an engineered bioweapon.

That said, its important to be upfront that we do not have sufficient evidence to exclude entirely the possibility that it escaped from a research lab doing gain of function experiments.

Carl T. Bergstrom

In summary, the hypothesis that the virus escaped from a lab is supported largely by circumstantial evidence and is not supported by genomic analyses and publicly available information. In the absence of evidence for or against an accidental lab leak, one cannot rule it out as the actual source of the outbreak. I dont think we have real data to say when these things began, in large part because the data are being held back from inspection, said Gerald Keusch, associate director of the Boston University National Emerging Infectious Diseases Laboratories, in this LiveScience article.

Given allegations of a cover-up, it appears that only an open and transparent review of the laboratory activities at WIV can allow us to confirm or reject this unlikely hypothesis.

[Back to top]

Hypothesis 3: The novel coronavirus evolved naturally and the outbreak began through zoonotic infection Virologists explain that the most likely hypothesis is that the outbreak started with a naturally-occurring zoonotic infectionone that is transmitted from animals to humansrather than a lab breach. This is largely due to what we know of the virus genomic features, which strongly indicate a natural origin. For example, if a virus had escaped from a laboratory, its genome would likely be most similar to those of the viral strains cultured in that lab. However, as shown in this phylogenetic tree by Bedford (see figure below), SARS-CoV-2 does not cluster in the same branch as the SARS-like coronavirus WIV1 (WIV1) and SARS-CoV-1, which are commonly cultured lab strains with the closest similarity to SARS-CoV-2 at the WIV facility, which is the lab that some have suggested might be a potential source of a lab leak. Instead, SARS-CoV-2 aligns most closely with coronaviruses isolated in the wild from bats and pangolins, indicating that it is more likely to have come from a natural source than from a lab:

FigurePhylogenetic tree showing evolutionary relationships between different coronavirusesmostly bat coronaviruses and some pangolin coronaviruses (by Trevor Bedford). Different lab strains of SARS-CoV-1 (referred to as SARS-CoV here) are represented by yellow dots. WIV1, another common lab strain, is indicated with a black arrow.

Furthermore, SARS-CoV-2 displays evolutionary features which suggest that the virus originated in animals and jumped to humans. The closest sequenced ancestor of SARS-CoV-2 is RaTG13, a bat coronavirus with about 96% genome sequence identity[8]. But SARS-CoV-2 also has features that distinguish it from RaTG13 and other SARS-like coronaviruses including SARS-CoV-1. As mentioned in the previous section, these features are: mutations in the receptor binding domain (RBD) of the S protein, a polybasic cleavage site, and a nearby O-linked glycan addition site in the S protein[4]. The mutations in the RBD of the S protein resemble those of some pangolin coronaviruses, suggesting that the virus made a jump from bats to an intermediate (perhaps pangolins), and then later to humans.

To briefly re-cap from the previous section discussing the hypothesis of a lab origin, Christian Stevens explained in this article that the polybasic cleavage site and the O-linked glycan additions to the S protein have not been identified in bat betacoronaviruses nor the pangolin betacoronaviruses sampled so far. However, evidence indicates that these features are much more likely to have arisen in the presence of an immune system, suggesting that this is a natural adaptation by the virus to a live host, either an animal or a human.

And again, there is no known animal model that would allow for selection of human-like ACE2 binding and avoidance of immune recognition, Stevens explained. This strongly suggests that SARS-CoV-2 could not have been developed in a lab, even by a system of simulated natural selection. In other words, the overall combination of features observed in SARS-CoV-2 is extremely unlikely to have arisen through experiments, even simulated evolution, because the experimental tools are not available at the moment.

Finally, Christian Stevens highlighted that the Ka/Ks ratio of the virus strongly indicates that the virus did not come from lab-simulated evolution. The Ka/Ks ratio calculates the level of synonymous mutations (which do not produce any functional change in proteins) and non-synonymous mutations (which produce functional changes in proteins). Non-synonymous mutations are more likely to occur in the presence of selective pressure, such as a need to adapt to a new environment:

Because synonymous mutations should have no effect, we expect them to happen at a relatively consistent rate. That makes them a good baseline that we can compare the number of non-synonymous mutations to. By calculating the ratio between these two numbers we can differentiate between three different types of selection:

We would expect a virus that is learning to exist in a new context would be undergoing Darwinian selection and we would see a high rate of non-synonymous changes in some part of the genome. This would be the case if the virus were being designed via simulated natural selection, we would expect at least some part of the genome to show Darwinian selection.

An analysis by Bedford demonstrates that the level of non-synonymous mutations between SARS-CoV-2 and the naturally occurring RaTG13 are highly similar, standing at 14.3% and 14.2%, respectively.

Both of these numbers indicate a purifying selection, with very few non-synonymous changes. This holds true across the entire genome with no part of it showing Darwinian selection. This is a very strong indicator that SARS-CoV-2 was not designed using forced selection in a lab, Stevens concluded.

[Back to top]

Conclusions Taken together, the information presented here suggests that it is much more likely that SARS-CoV-2 was generated naturally and transmitted zoonotically, without any engineering or lab growth. Especially given the fact that the prior probability for the zoonotic hypothesis is high. Indeed, zoonotic infections (transmission of pathogens from animals/insects to humans) are not only plausible but common throughout the world, and have also caused outbreaks in the past. For example, the SARS outbreak, which began in 2002, was linked to civet cats. Outbreaks of Middle East respiratory syndrome have been linked to contact with camels. Nipah virus infection has been linked to fruit bats and caused outbreaks in Asia. Mosquitoes transmit viruses such as Zika, dengue, and chikungunya, while ticks also carry a range of pathogens, such as Lyme disease and Rocky Mountain spotted fever. In fact, according to the World Health Organization, about 60% of emerging diseases are zoonotic infections.

In summary, the hypothesis that the virus escaped from a lab is supported largely by circumstantial evidence and is not supported by publicly available information. In the case of the hypothesis that the outbreak began with zoonotic infection, at the moment genomic analyses are consistent with a natural origin for the virus and support the idea that the outbreak began zoonotically. Unlike the manmade virus and lab escape hypotheses, there is no compelling evidence against the hypothesis for natural zoonosis. As Stevens concluded, the hypothesis for natural zoonosis is the one that fits all available evidence, is most parsimonious, and best satisfies the concept of Occams Razorthat the simplest solution is most likely the right one.

[Back to top]

Christian Stevens from the Benhur Lee lab at the Mount Sinai School of Medicine has provided a comprehensive explanation of the multiple scientific studies examining the origin of the coronavirus.

Scientists explained in this 23 April NPR article why they found the lab accident hypothesis unlikely. In fact, the article states that there is virtually no chance that the new coronavirus was released as result of a laboratory accident in China or anywhere else.

Read the original here:
Did the COVID-19 virus originate from a lab or nature? Examining the evidence for different hypotheses of the novel coronavirus' origins - Health...

Read More...

Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race – Salon

Sunday, April 26th, 2020

There has beenno scientific findingthat the novel coronavirus was bioengineered, but its origins are not entirely clear. Deadly pathogens discovered in the wild are sometimesstudied inlabs and sometimes made more dangerous. That possibility, and other plausible scenarios, have been incorrectly dismissed in remarks by some scientists andgovernment officials, and in the coverage of most major media outlets.

Regardless of the source of this pandemic, there is considerable documentation that a global biological arms race going on outside of public view could produce even more deadly pandemics in the future.

While much of the media and political establishment have minimized the threat from such lab work, some hawks on the American right like Sen. Tom Cotton, R-Ark., have singled outChinese biodefense researchers as uniquely dangerous.

But there is every indication that U.S. lab work is every bit as threatening as that in Chinese labs. American labs also operate insecret, and are also known to beaccident-prone.

The current dynamics of the biological arms race have been driven by U.S. government decisions that extend back decades. In December 2009, Reuters reported that the Obama administration was refusing even to negotiate the possible monitoring of biological weapons.

Advertisement:

Much of the left in the U.S. now appears unwilling to scrutinize the origin of the pandemic or the wider issue of biowarfare perhaps because portions of the anti-Chinese right have been sovocal in making unfoundedallegations.

Governments that participate in such biological weapon research generally distinguish between "biowarfare" and "biodefense," as if to paint such "defense" programs as necessary. But this is rhetorical sleight-of-hand; the two concepts are largely indistinguishable.

"Biodefense" implies tacit biowarfare, breeding more dangerous pathogens for the alleged purposeof finding a way tofightthem. While this work appears to have succeeded in creating deadly and infectious agents, including deadlier flu strains, such "defense" research is impotent in its ability to defend us from this pandemic.

The legal scholar who drafted the main U.S. law on the subject, Francis Boyle, warned in his 2005 book "Biowarfare and Terrorism" that an "illegal biological arms race with potentially catastrophic consequences" was underway, largely driven by the U.S. government.

For years,many scientistshave raised concerns regarding bioweapons/biodefense lab work, and specifically aboutthe fact that huge increases in funding have taken place since 9/11. This was especially true afterthe anthrax-by-mail attacks that killed five people in the weeks after 9/11, which the FBI ultimately blamed on a U.S. government biodefense scientist.A 2013 study found that biodefense funding since2001 hadtotaled at least $78 billion, and more has surely been spent since then. This has led to aproliferation of laboratories, scientists and new organisms, effectively setting off a biological arms race.

Following the Ebola outbreak in west Africa in 2014, the U.S. governmentpaused fundingfor what are known as "gain-of-function" research on certain organisms. This work actually seeks to make deadly pathogensdeadlier, in some cases making pathogens airborne thatpreviously were not. With little notice outside the field, the pause on such research was lifted in late 2017.

During this pause, exceptions for funding were made for dangerous gain-of-function lab work. This included work jointly done by U.S. scientists from the University of North Carolina, Harvard and the Wuhan Institute of Virology. This work which had funding from USAID and EcoHealth Alliance not originally acknowledged was published in2015 in Nature Medicine.

A different Nature Medicine article about the origin of the current pandemic,authored by five scientists andpublished on March 17,has been touted by major media outlet and some officials including current National Institutes of Health directorFrancis Collins as definitively disproving a lab origin for the novel coronavirus. That journal article, titled "The proximal origin of SARS-CoV-2," stated unequivocally: "Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus." This is a subtly misleading sentence. While the scientists state that there is no known laboratory "signature" in the SARS-Cov-2 RNA, their argument fails to take account of other lab methods that could have created coronavirus mutations without leaving such a signature.

Indeed, there is also thequestion of conflict of interest in the Nature Medicine article. Some of the authors of that article, as well as aFebruary 2020Lancet letter condemning "conspiracy theories suggesting that COVID-19 does not have a natural origin" which seemed calculated to minimize outside scrutiny of biodefense lab work have troubling ties to thebiodefense complex,as well as to the U.S. government. Notably, neither of these articles makes clear that a virus can have a natural originand then be captured and studied in a controlled laboratory setting before being let loose, either intentionally or accidentallywhichis clearly a possibility in the case of the coronavirus.

Facts as "rumors"

This reporter raised questions about the subject at a news conference with a Center for Disease Control (CDC) representative at the now-shuttered National Press Club on Feb. 11. I asked if it was a "complete coincidence" that the pandemic had started in Wuhan, the only place in China with a declared biosafety level 4 (BSL4) laboratory. BSL4 laboratories have the most stringent safety mechanisms, but handle the most deadly pathogens. As I mentioned, it was oddthat the ostensible origin of the novel coronavirus was bat caves in Yunnan province more than 1,000 miles from Wuhan. I noted that "gain-of-function" lab work can results in more deadly pathogens, and that major labs, including some in the U.S., have had accidental releases.

CDC Principal Deputy Director Anne Schuchat saidthatbased on the information she had seen, the virus was of "zoonotic origin." She also stated, regarding gain-of-function lab work, that it is important to "protect researchers and their laboratory workers as well as the community around them and that we use science for the benefit of people."

I followed up by asking whether an alleged natural origin did not preclude the possibility that this virus came through a lab, since a lab could have acquired a bat virus and been working on it. Schuchat replied to the assembled journalists that "it is very common for rumors to emerge that can take on life of their own," but did not directly answer the question. She noted that in the 2014 Ebola outbreak some observers had pointed to nearby labs as the possible cause, claiming this "was a key rumor that had to be overcome in order to help control the outbreak." She reiterated: "So based on everything that I know right now, I can tell you the circumstances of the origin really look like animals-to-human. But your question, I heard."

This is no rumor. It's a fact: Labs work with dangerous pathogens. The U.S. and China each have dual-use biowarfare/biodefense programs. China has major facilities at Wuhan a biosafety level 4 lab and a biosafety level 2 lab. There are leaks from labs. (See "Preventing a Biological Arms Race," MIT Press, 1990, edited by Susan Wright; also, a partial review in Journal of International Law from October 1992.)

Much of the discussion of this deadly serious subject is marred with snark that avoids or dodges the "gain-of-function" question. ABC ran a story on March 27 titled "Sorry, Conspiracy Theorists. Study Concludes COVID-19 'Is Not a Laboratory Construct.'" That story did not address the possibility that the virus could have been found in the wild, studied in a lab and thenreleased.

On March 21, USA Today published a piece headlined "Fact Check: Did the Coronavirus Originate In a Chinese Laboratory?" and rated it "FALSE."

That USA Today story relied on the Washington Post, which publishedawidely cited article onFeb.17headlined,"Tom Cotton keeps repeating a coronavirus conspiracy theory that was already debunked." That article quoted public comments fromRutgers University professor of chemical biology Richard Ebright, but out of context and only in part. Specifically, the story quoted from Ebright's tweet that the coronavirus was not an "engineered bioweapon." In fact, his full quote included the clarification that the virus could have "entered human population through lab accident." (An email requesting clarification sent toPost reporterPaulina Firoziwas met with silence.)

Bioengineered From a lab

Other pieces in the Post since then (some heavily sourced to U.S. government officials) have conveyed Ebright's thinking, but it gets worse. In a private exchange, Ebright who, again, has said clearly that the novel coronavirus was not technically bioengineered using known coronavirus sequences stated that other forms of lab manipulation could have beenresponsible for the current pandemic. This runs counter to much reporting, which is perhaps too scientifically illiterate to perceive the difference.

In response to the suggestion that the novel coronavirus could have come about through various methodsbesides bioengineering made by Dr. Meryl Nass, who has done groundbreaking work on biowarfareEbright responded in an email:

The genome sequence of SARS-CoV-2 has no signatures of human manipulation.

This rules out the kinds of gain-of-function (GoF) research that leave signatures of human manipulation in genome sequences (e.g., use of recombinant DNA methods to construct chimeric viruses), but does not rule out kinds of GoF research that do not leave signatures (e.g., serial passage in animals). [emphasis added]

Very easy to imagine the equivalent of the Fouchier's "10 passages in ferrets" with H5N1 influenza virus, but, in this case, with 10 passages in non-human primates with bat coronavirus RaTG13 or bat coronavirus KP876546.

That last paragraph is very important. It refersto virologist Ron Fouchier of the Erasmus Medical Center in Rotterdam, who performed research on intentionally increasing rates of viralmutation rate by spreading a virus from one animal to another in a sequence.The New York Times wrote about this in an editorial in January 2012, warning of "An Engineered Doomsday."

"Now scientists financed by the National Institutes of Health" have created a "virus that could kill tens or hundreds of millions of people" if it escaped confinement, the Times wrote. The story continued:

Working with ferrets, the animal that is most like humans in responding to influenza, the researchers found that a mere five genetic mutations allowed the virus to spread through the air from one ferret to another while maintaining its lethality. A separate study at the University of Wisconsin, about which little is known publicly, produced a virus that is thought to be less virulent.

The word "engineering" in the New York Times headline is technically incorrect, sincepassing a virus through animals is not "genetic engineering." This same distinction has hindered some from understanding the possible origins of the current pandemic.

Fouchier's flu work, in which an H5N1 virus was made more virulent by transmitting it repeatedly between individual ferrets, briefly sent shockwaves through the media. "Locked up in the bowels of the medical faculty building here and accessible to only a handful of scientists lies a man-made flu virus that could change world history if it were ever set free," wrote Science magazine in 2011 in a story titled "Scientists Brace for Media Storm Around Controversial Flu Studies." It continues:

The virus is an H5N1 avian influenza strain that has been genetically altered and is now easily transmissible between ferrets, the animals that most closely mimic the human response to flu. Scientists believe it's likely that the pathogen, if it emerged in nature or were released, would trigger an influenza pandemic, quite possibly with many millions of deaths.

In a 17th floor office in the same building, virologist Ron Fouchier of Erasmus Medical Center calmly explains why his team created what he says is "probably one of the most dangerous viruses you can make" and why he wants to publish a paper describing how they did it. Fouchier is also bracing for a media storm. After he talked to ScienceInsider yesterday, he had an appointment with an institutional press officer to chart a communication strategy.

Fouchier's paper is one of two studies that have triggered an intense debate about the limits of scientific freedom and that could portend changes in the way U.S. researchers handle so-called dual-use research: studies that have a potential public health benefit but could also be useful for nefarious purposes like biowarfare or bioterrorism.

Despite objections, Fouchier's article was published by Science in June 2012. Titled "Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets," it summarized how Fouchier's research team made the pathogen more virulent:

Highly pathogenic avian influenza A/H5N1 virus can cause morbidity and mortality in humans but thus far has not acquired the ability to be transmitted by aerosol or respiratory droplet ("airborne transmission") between humans. To address the concern that the virus could acquire this ability under natural conditions, we genetically modified A/H5N1 virus by site-directed mutagenesis and subsequent serial passage in ferrets. The genetically modified A/H5N1 virus acquired mutations during passage in ferrets, ultimately becoming airborne transmissible in ferrets.

In other words, Fouchier's research took a flu virus that did not exhibit airborne transmission, then infected a number of ferrets until it mutated to the point that it was transmissible by air.

In thatsame year, 2012, asimilar studyby Yoshihiro Kawaoka of the University of Wisconsin was published in Nature:

Highly pathogenic avian H5N1 influenza A viruses occasionally infect humans, but currently do not transmit efficiently among humans. ... Here we assess the molecular changes ... that would allow a virus ... to be transmissible among mammals. We identified a ... virus ... with four mutations and the remaining seven gene segments from a 2009 pandemic H1N1 virus that was capable of droplet transmission in a ferret model.

In 2014, Marc Lipsitch of Harvard and Alison P. Galvani of Yale wrote regarding Fouchier and Kawaoka's work:

Recent experiments that create novel, highly virulent and transmissible pathogens against which there is no human immunity are unethical ... they impose a risk of accidental and deliberate release that, if it led to extensive spread of the new agent, could cost many lives. While such a release is unlikely in a specific laboratory conducting research under strict biosafety procedures, even a low likelihood should be taken seriously, given the scale of destruction if such an unlikely event were to occur. Furthermore, the likelihood of risk is multiplied as the number of laboratories conducting such research increases around the globe.

Given this risk, ethical principles, such as those embodied in the Nuremberg Code, dictate that such experiments would be permissible only if they provide humanitarian benefits commensurate with the risk, and if these benefits cannot be achieved by less risky means.

We argue that the two main benefits claimed for these experiments improved vaccine design and improved interpretation of surveillance are unlikely to be achieved by the creation of potential pandemic pathogens (PPP), often termed "gain-of-function" (GOF) experiments.

There may be a widespread notion that there is scientific consensus that the pandemic did not come out of a lab. But in factmany of the most knowledgeable scientists in the field are notably silent. This includes Lipsitch at Harvard, Jonathan A. King at MITand many others.

Just last year, Lynn Klotz of the Center for Arms Control and Non-Proliferation wrote a paperin the Bulletin of the Atomic Scientistsentitled "Human Error in High-biocontainment Labs: A Likely Pandemic Threat." Wrote Klotz:

Incidents causing potential exposures to pathogens occur frequently in the high security laboratories often known by their acronyms, BSL3 (Biosafety Level 3) and BSL4. Lab incidents that lead to undetected or unreported laboratory-acquired infections can lead to the release of a disease into the community outside the lab; lab workers with such infections will leave work carrying the pathogen with them. If the agent involved were a potential pandemic pathogen, such a community release could lead to a worldwide pandemic with many fatalities. Of greatest concern is a release of a lab-created, mammalian-airborne-transmissible, highly pathogenic avian influenza virus, such as the airborne-transmissible H5N1 viruses created in the laboratories of Ron Fouchier in the Netherlands and Yoshihiro Kawaoka in Madison, Wisconsin.

"Crazy, dangerous"

Boyle, a professor of international law at the University of Illinois, has condemned Fouchier, Kawaoka and others including at least one of the authors of the recent Nature Medicine article in the strongest terms, calling such work a "criminal enterprise." While Boyle has been embroiled in numerous controversies, he's been especially dismissed by many on this issue. The "fact-checking" websiteSnopeshas described him as "a lawyer with no formal training in virology" without noting that he wrote the relevant U.S. law.

As Boyle saidin 2015:

Since September 11, 2001, we have spent around $100 billion on biological warfare. Effectively we now have an Offensive Biological Warfare Industry in this country that violates theBiological Weapons Conventionand myBiological Weapons Anti-Terrorism Act of 1989.

The law Boyle drafted states: "Whoever knowingly develops, produces, stockpiles, transfers, acquires, retains, or possesses any biological agent, toxin, or delivery system for use as a weapon, or knowingly assists a foreign state or any organization to do so, shall be fined under this title or imprisoned for life or any term of years, or both. There is extraterritorial Federal jurisdiction over an offense under this section committed by or against a national of the United States."

Boyle also warned:

Russia and China have undoubtedly reached the same conclusions I have derived from the same open and public sources, and have responded in kind. So what the world now witnesses is an all-out offensive biological warfare arms race among the major military powers of the world: United States, Russia, Britain, France, China, Israel, inter alia.

We have reconstructed the Offensive Biological Warfare Industry that we had deployed in this county before its prohibition by the Biological Weapons Convention of 1972, described by Seymour Hersh in his groundbreaking expose "Chemical and Biological Warfare: America's Hidden Arsenal." (1968)

Boyle now states that he has been "blackballed" in the media on this issue, despite his having written the relevant statute. The group he worked with on the law, the Council for Responsible Genetics, went under several years ago, making Boyle's views against "biodefense" even more marginal as government money for dual use work poured into the field and criticswithin the scientific community have fallen silent. In turn, his denunciationshave grown more sweeping.

In the 1990 book "Preventing a Biological Arms Race," scholar Susan Wright argued that current laws regarding bioweapons were insufficient, as there were "projects in which offensive and defensive aspects can be distinguished only by claimed motive." Boyle notes, correctly, that current law he drafted does not makean exception for "defensive" work, but only for "prophylactic, protective or other peaceful purposes."

While Boyle is particularly vociferous in his condemnations, he is not alone. There has been irregular, but occasional media attention to this threat. The Guardian ran a piece in 2014,"Scientists condemn 'crazy, dangerous' creation of deadly airborne flu virus," afterKawaoka created a life-threatening virus that "closely resembles the 1918 Spanish flu strain that killed an estimated 50m people":

"The work they are doing is absolutely crazy. The whole thing is exceedingly dangerous," said Lord May, the former president of the Royal Society and one time chief science adviser to the UK government. "Yes, there is a danger, but it's not arising from the viruses out there in the animals, it's arising from the labs of grossly ambitious people."

Boyle'scharges beginning early this yearthat the coronavirus was bioengineered allegationsrecently mirrored by French virologist andNobel laureate Luc Montagnier have not been corroborated by any publicly produced findings of any U.S. scientist. Boyle even charges that scientists like Ebright, who is at Rutgers, arecompromised because the university got abiosafety level 3 lab in 2017though Ebright is perhaps the most vocal eminent critic of this research, among U.S. scientists. These and other controversies aside, Boyle's concerns about the dangers of biowarfare arelegitimate; indeed, Ebright shares them.

Some of the most vocal voices to discuss the origins of the novel coronavirushave been eager to minimizethe dangers of lab work, or have focused almost exclusively on "wet markets" or "exotic" animals as the likely cause.

The media celebrated Laurie Garrett, the Pulitzer Prizewinning author and former senior fellow at the Council on Foreign Relations, when she declared on Twitter on March 3 (in a since-deleted tweet)that the origin of the pandemic was discovered: "It's pangolins. #COVID19 Researchers studied lung tissue from 12 of the scaled mammals that were illegally trafficked in Asia and found #SARSCoV2 in 3. The animals were found in Guangxi, China. Another virus+ smuggled sample found in Guangzhou."

She was swiftly corrected by Ebright: "Arrant nonsense. Did you even read the paper? Reported pangolin coronavirus is not SARS-CoV-2 and is not even particularly close to SARS-CoV-2. Bat coronavirus RaTG13 is much closer to SARS-CoV-2 (96.2% identical) than reported pangolin coronavirus (92.4% identical)." He added: "No reason to invoke pangolin as intermediate. When A is much closer than B to C, in the absence of additional data, there is no rational basis to favor pathway A>B>C over pathway A>C." When someone asked what Garrett was saying, Ebright responded: "She is saying she is scientifically illiterate."

The following day, Garrett corrected herself (without acknowledging Ebright): "I blew it on the #Pangolins paper, & then took a few hours break from Twitter. It did NOT prove the species = source of #SARSCoV2. There's a torrent of critique now, deservedly denouncing me & my posting. A lot of the critique is super-informative so leaving it all up 4 while."

At leastone Chinese governmentofficialhas respondedto the allegation that the labs in Wuhan could be the source for the pandemic by alleging that perhaps the U.S. isresponsibleinstead. In American mainstreammedia, that has been reflexivelytreated as evenmore ridiculousthan the original allegation that the virus could havecome froma lab.

Obviouslythe Chinese government'sallegations should not be taken at face value, but neither should U.S. government claims especially considering that U.S. government labs were the apparent source for theanthrax attacks in 2001. Those attacks sent panic through the U.S. and shut down Congress, allowing the Bushadministration to enact the PATRIOT Act and ramp up the invasions of Afghanistan and Iraq. Indeed, in October2001, media darlings like Richard Butler and Andrew Sullivan propagandizedfor war with Iraq because of the anthrax attacks. (Neither Iraq nor al-Qaida was involved.)

The 2001 anthrax attacks also provided muchof the pretext forthe surge in biolab spending since then, even though they apparently originated in a U.S. or U.S.-allied lab. Indeed, thoseattacks remain shrouded in mystery.

The U.S. government has also come up withelaborate cover stories to distract from its bioweapons work. For instance, the U.S. government infamously claimed the 1953 death of Frank Olson, a scientist at Fort Detrick, Maryland, was anLSD experiment gone wrong;it now appears to have been an execution to cover up for U.S.biological warfare.

Regardless of the cause of the current pandemic, these biowarfare/biodefense labs need far more scrutiny. The call to shut them down by Boyle and others needs to be clearly heard and light must be shone on precisely what research is being conducted.

The secrecy of these labs may prevent us ever knowing with certainty the origins of the current pandemic.What we do know is this kind of lab work comes with real dangers. One might make a comparison to climate change: We cannot attribute an individual hurricane to man-made climate disruption,yet science tells us that human activity makes stronger hurricanes more likely. Thatbrings us back to the imperative to cease the kinds of activities thatproduce such dangers in the first place.

If that doesn't happen, the people of the planet will be at the mercy of the machinations and mistakes of state actors who are playing with fire for their geopolitical interests.

View original post here:
Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race - Salon

Read More...

Comment: Nassau executive chef Silvena Rowe on biohacking the body – Caterer Middle East

Sunday, April 26th, 2020

As the coronavirus pandemic continues unabated around the world, we are, understandably, all concerned about the best ways to protect ourselves against viruses and other infections.

First and foremost, we all need to follow government advice to stay home and social distance. But, beyond this, we can all use the time to rest up and dose up so that when we are able to get back to work, we are geared up to stay healthy and thrive.

I consider myself a natural biohacking expert. Biohacking is the practice of enhancing our bodies and our health through science and self-experimentation. It can be as simple as implementing lifestyle and dietary changes that improve the functioning of your body, or as extreme as using implant technology and genetic engineering. I believe in the power of food, utilising the natural chemistry of the body and good cognitive function to slow the ageing process, strengthen our immune systems and generally make us superhuman.

Incorporating some of these simple biohacks into your routine is the most effective way to ensure your defences are as effective as they can be against viral infection and pathogens.

You are what you eat (and put anywhere near your body)

We are, quite literally, what we eat. We live in a symbiotic relationship with around 30 trillion microbes that live in our bodies, collectively making up our microbiome. Our microbiome programmes our immune system and is strengthened by fermented foods, fibre, pulses and plant-based food in general. Make sure you eat as balanced a diet as possible. Otherwise, you are just leaving the door open for enemy viruses to walk straight in and start making themselves at home. Superfoods that feature in my diet everyday include bee pollen (an antioxidant that speeds up healing) aai (contains healthy fats and could be anti-cancer agent) and blue spirulina (improves muscles strength and endurance).

Use supplements strategically

I use a range of supplements to complement my diet and ensure I am giving my body the nutrients it needs to stay healthy. The combination you take will depend on your age, gender, whether youre pregnant and even where you live. Vitamin D is advised for most people, particularly as it can be difficult to get enough through your diet alone. These nutrients are needed to keep bones, teeth and muscles healthy. Echinacea is one of the most popular immune-boosting herbs, it can reduce inflammation and has been found to shorten the duration of flu-like viruses. I also take vitamin C, zinc and probiotic supplements.

Stay active- but rest is just as important

To enjoy a functioning immune system it will come as no surprise that exercise is key, but the impact that sleep has on our bodies is less well known. In our industry, were used to a work hard, play hard culture, but if were not getting enough sleep then were putting ourselves at risk of burning out and succumbing to illness. Long-term, a lack of sleep can increase the risk of conditions such as heart disease, diabetes and obesity. Sleep is your bodys time to repair and reset- and it will switch off your bodys chemical stress response too.

The current public health emergency has given us all time to pause and reflect. If youre lucky enough to be able to stay home and stay safe, why not try to incorporate some of these natural bio hacks into your life? Youll feel the benefits in no time.s

Continue reading here:
Comment: Nassau executive chef Silvena Rowe on biohacking the body - Caterer Middle East

Read More...

Episode 190: Genetics and Nazism – Jewish Journal

Sunday, April 26th, 2020

We all want to be the best we can be. And of course, we want to surround ourselves with the best of the best. But this seemingly positive motive has led some people to say and do some pretty horrific things throughout history.

The Greek Philosopher Plato suggested selective mating to breed a higher class of humans. In Sparta, a council of elders inspected every child to determine if he or she was fit to live. In early ancient Rome, fathers were expected to immediately kill their child if they were disabled in any way.

But its not just ancient history. In the 19th and 20th century a new system of beliefs began to emerge Eugenics. The idea that through selective breeding we can improve the genetic make-up of the human race. Sound familiar?

But where did Eugenic thought originate?

Professor Amir Teicher discusses exactly that in his new book, Social Mendelism: Genetics and the Politics of Race in Germany, 1900-1948 Professor Teicher is an assistant professor of history at the University of Tel Aviv. His research is focused on Germany, eugenics, the development of modern biological thinking, racism and antisemitism, and the history of medicine.

We are super thrilled to be joined today by Professor Amir Teicher to talk about his new book and the history of Eugenics.

More:
Episode 190: Genetics and Nazism - Jewish Journal

Read More...

Meet the 5 female finalists for the 2020 M&T Bank John Travers Award – PennLive

Sunday, April 26th, 2020

For the 39th year, M&T Bank, in conjunction with PennLive and the Harrisburg Lions Club, has been honoring central Pa.s top student-athletes with the John Travers Award.

The 2020 finalists have all excelled as athletes, students, and voices in their communities. Today, we shine a spotlight on the 5 female finalists.

Winners will be announced next month along with the A.I. Garner Outstanding Coach Award winner. The Travers Award is named for the late executive sports editor of The Patriot-News.

Gabriella Recce, Central Dauphin

Gabriella Recce Central Dauphin track and field during media day on February 28, 2019.Sean Simmers | ssimmers@pennlive.comPENNLIVE.COM

Varsity sports: Track and Field (4 letters), Indoor Track (3 letters), Golf (4 letters), Cheerleading (1 letter), Swimming (1 letter)

College choice: University of Virginia

Finalists voice: I chose to pursue engineering as my career, because engineers can change the way we live in the world. Whether eradicating cancer and other debilitating diseases, improving our health with stem cell therapies, cleaning the environment with sustainable approaches or creating novel transportation methods, engineers are trained to solve problems and generate new solutions. My passion for this career comes from my dedication to my academic journey, my learning as a multi-event athlete and the support and encouragement of my family.

Describe yourself in one word: Positive

Gabriella Recce of Central Dauphin competes in the girls 3A long jump during the District 3 Track & Field Championships at Shippensburg University on May 18, 2019.Joe Hermitt | jhermitt@pennlive.com

Accomplishments: Theres no question Recce was aligned for a terrific final season in track and field. Earning three PIAA medals in the pole vault, long jump and triple jump at last years PIAA Championship meet, Recce was poised to add a few more records to her already glowing career. Shes earned a dozen top finishes during Mid-Penn and District 3 competitions. Plus, she qualified and competed at the prestigious Penn Relays, New Balance Outdoor and Indoor National competitions along the way. Recce was coming off an outstanding Indoor season when the spring sports calendar was canceled due to the coronavirus pandemic. Reece, also an accomplished golfer, helped the Rams golf team win a District 3 title in 2017. Vice-President of CDs National Honors Society, Recce also served as Editor of the Key Club and volunteered with PAWS, LPGA Girls Golf of Harrisburg, the Four Diamonds Club and PanRam Field Day for special needs students. In addition, the senior won a national gold medal in scholastic art and writing (2016) and was part of Hershey Medical Centers PULSE Program.

Katie Sajer, Trinity

Katie Sajer (20) of Trinity girls basketball during Mid-Penn basketball media day on Nov. 14, 2019.Dan Gleiter | dgleiter@pennlive.com

Varsity sports: Volleyball (4 letters), Basketball (4 letters), Lacrosse (4 letters)

College choice: University of Notre Dame

Finalists voice: The ROTC program offers chances to earn skill sets and exposure otherwise unavailable to civilians. These skills will be necessary to ensure the lives and safety of my team. By using my athleticism in this regard, I will be able to give back to the country that has made me into the person I am today, and fight for the people who came before me. I will be able to make a larger impact through this use of my athleticism than anything I would be able to do on the athletic field or court.

Describe yourself in one word: Hard-working

Trinity's Katie Sajer drives past a Central Dauphin defender during Central Dauphins 55-42 win over Trinity in the Mid-Penn girls basketball championship, February 13, 2020.Vicki Vellios Briner | Special to PennLiveVicki Vellios Briner | Special to PennLive

Accomplishments: Among the most versatile athletes in the Mid-Penn Conference, Sajer captained a pair of Trinity sports programs and is a two-time All-State pick in volleyball. In fact, Sajer was a 2019 nominee for the Under Armour High School All-American volleyball team. Awarded a national four-year Army ROTC Scholarship at Notre Dame, Duke University, the University of Delaware and Bucknell University, Sajer opted to focus on physical, mental and leadership training in South Bend. Sajer has worked as marketing intern for Pennsylvania Wounded Warriors, developing a campaign that has raised approximately $145,000 to support servicemen and women in Pa. Sajer, a member of Trinitys French Foreign Language Honors Society, also served as a property manager in her family business, and worked as a school mentor and activities leader.

Gery Schnarrs, East Pennsboro

Gery Schnarrs of East Pennsboro field hockey during high school football media day on July 31, 2019.Sean Simmers | ssimmers@pennlive.com

Varsity sports: Field Hockey (4 letters), Track and Field (2 letters)

College choice: University of Virginia

Finalists voice: I would tell young athletes to stay at it. Obviously, you are going to face a lot of obstacles. You are going to think a lot of times that, maybe if you dont make a team, you should move on to something different? I think its important to stay at it and keep following what you want to do. I think thats how you succeed. If you want to do it, then I think thats where youre going to put most of your effort.

Describe yourself in one word: Determined

Gery Schnarrs, East Pennsboro M/D (Univ. of Virginia). The Mid-Penn is overflowing with field hockey players who will take their talents to the next level. Oct. 24, 2019. Sean Simmers | ssimmers@pennlive.com

Accomplishments: Ever since the Virginia recruit broke onto the field hockey scene, scoring 10 goals with 12 assists as a freshman, Schnarrs has impacted the Mid-Penn Conference and beyond. A current member of USA Womens National Indoor Development team, Schnarrs capped her brilliant run with a spot on Max Field Hockeys HS All-American team. She holds East Pennsboro career mark with 198 points and earned multiple All-State appointments. The Panthers won four straight division titles, and four trips to states, with No. 37 digging in. A Scholar of Distinction on the National Field Hockey Coaches Association Academic team, Schnarrs has served as treasurer for three different school programs, including that National Honors Society. A Girl Scouts Gold Award winner through her Get in the Game initiative. Schnarrs also won a Silver Presidential Volunteer Service Award last year and coordinated multiple service drives like Purses for a Purpose for the homeless and a bedding rive for the Speranza Animal Shelter. Shes also volunteered with the Bethesda Mission Womens Shelter, Salvation Army and more.

Marlee Starliper, Northern

Northern's Marlee Starliper shows off her NC State gear Sunday after committing to the Wolfpack.

Varsity sports: Cross Country (4 letters), Track and Field (4 letters), Indoor Track (4 letters)

College choice: North Carolina State

Finalists voice: I aspire to run professionally after college with the hope of having a long career in which I can pursue qualifying for several Olympic teams. Another aspect of y athletic goals is to continue enjoying the sport, have fun discovering more of my capabilities, and be a positive impact within the running community and beyond.

Describe yourself in one word: Passionate

Northern's Marlee Starliper trails Greencastle's Taryn Parks in the AAA 1600 meter run during day 2 of the 2019 PIAA Track and Field Championships at Shippensburg University. May 25, 2019 Sean Simmers | ssimmers@pennlive.comPENNLIVE.COM

Accomplishments: Starlipers resume is overflowing with state and national records, including three consecutive PIAA cross country titles. She was runner-up as a freshman. Pa.s Gatorade Cross County Player of the Year three times, Starliper also twice claimed Foot Locker Northeast regional titles and was runner-up at Foot Locker Nationals in the fall. She now holds the states all-time mark. On the track, Starliper is a four-time state champion and her mile (4:37) and 3k (9:07) standards rank No. 1 nationally. Invited to the Reykjavik Games in Iceland by the National Scholastic Athletic Foundation, Starliper finished third in the 800. Shes also competed for USATF in the Pan-American Games in Costa Rica, becoming a U20 national champion. An active member of the World Harvest Outreach Church in Chambersburg, Starliper has participated in Direct Call, a student-led Christian group at Northern, volunteered as a Special Olympics buddy and served a regular speaker to middle school cross country and tracks teams about nutrition. Recently, Starliper signed to write and illustrate a childrens book in Spanish.

Maddie Zimmer, Hershey

Maddie Zimmer, Hershey MF (Northwestern). The Mid-Penn is overflowing with field hockey players who will take their talents to the next level. Oct. 24, 2019. Sean Simmers | ssimmers@pennlive.com

Varsity sports: Field Hockey (4 letters), Lacrosse (3 letters)

College choice: Northwestern University

Finalists voice: This winter Ive actually been helping to coach at multiple field hockey clubs. I never thought I would like it, but I actually really like coaching the little girls. I didnt think I had the patience for it, but they improved so much and its so rewarding to see how excited they are. Thats how I was when I was their age. All I wanted to do was play field hockey and its so exciting to be a part of their journey. Its so rewarding and fun to watch.

Describe yourself in one word: Dedicated

Hershey's Maddie Zimmer brings the ball down field against Lower Dauphin in their high school field hockey game at Hershey. Sept. 11, 2019.Sean Simmers | ssimmers@pennlive.com

Accomplishments: As one of the nations top field hockey players in her class, Zimmer is a four-time All-State pick and high school All-American in her final two seasons. The midfielder also led the Trojans to the PIAA Class 3A title in 2018. She also earned US Lacrosse All-American honors as a junior. Continuing to rehab an ACL tear she suffered in November, Zimmer is planning to compete for the U21 U.S. National Field Hockey Team against Ireland in June. Her first cap came against Canada last summer. After Ireland will be the Junior Pan American Games in Chile, an official qualifier for the 21 Junior World Cup. Continuing to make an impact in her community, Zimmer has coached youth field hockey and lacrosse programs, donated her time to Purses full of Hope, raised funds for the Walk for Clean Water Organization and co-chaired the Herren Project, a non-profit that supports families with addiction and prevention of substance abuse.

2020 Travers Award female nominees

Follow Eric Epler on Twitter -- @threejacker

Thanks for visiting PennLive. Quality local journalism has never been more important. We need your support. Not a subscriber yet? Please consider supporting our work.

Originally posted here:
Meet the 5 female finalists for the 2020 M&T Bank John Travers Award - PennLive

Read More...

Healthy eyesight: Exercises to keep your peepers in top form – The South African

Sunday, April 26th, 2020

Exercising your eyes can keep your eyesight stronger for longer.

Just like the rest of your body, your face and eyes have muscles. Because of overuse, your eye muscles may become weak and you may be unable to see as clearly. If you regularly exercise your eyes you can keep your eyes safe and healthy.

Rub your palms vigorously until moist, and then gently place them over your eyelids. Let the palm warmth transfer to the head. You can feel the muscles of the eye relax as your eyes find comfort in the night. Persist until eyes completely absorb the heat from the palms. Repeat two to three times daily.

Sit back on your chair or bed with open eyes. Blink rapidly 10 to 15 times. Close your eyes, and take 20 seconds to relax. Repeat five times.

Another successful eye practice is to zoom in. As you might have inferred from the name, you are zooming in on an object to change your visions focus. Sit with your arm extended with your thumb up. Now, slowly bend your wrist, and bring your hand closer to your head, until you thumb is in focus.

Shifting is about shifting the eyeballs or turning them from one direction to another. Look to the right corner, then slowly turn your attention in the opposite direction. With the spurt of blood pumped in from the move, the tiny eye muscles get more active and healthy.

Carrot eating is good for your vision. Carrots are rich in vitamin A, an essential vision nutrient. Vitamin A is not the only vitamin that promotes healthy eye function, however. Make sure your diet contains foods that are rich in vitamin C, vitamin E, copper and zinc.

Its good to close your eyes just for a few minutes. If youre hard at work, you can do this once an hour, or several times. So if your work includes sitting in front of a computer or reading it can be soothing to close your eyes. This exercise, as basic as it sounds, will protect the eyes from over-exertion or fatigue.

This content has been created as part of our freelancer relief programme. We are supporting journalists and freelance writers impacted by the economic slowdown caused by #lockdownlife.

If you are a freelancer looking to contribute to The South African,read more here.

View post:
Healthy eyesight: Exercises to keep your peepers in top form - The South African

Read More...

Bringing the benefits of eye-care to vulnerable children – The Irish Times

Sunday, April 26th, 2020

Diagnostic overshadowing is not a term which makes it into the mainstream media very often. It refers to a tendency to attribute all of a patients problems to a major condition, thereby allowing other co-existing conditions go undiagnosed.

It is a particular problem for people with learning disabilities, who often find health professionals make assumptions that their behaviour is a part of their disability without exploring other factors such as biological determinants.

This is an area which has interested Kathryn Saunders, professor of optometry and vision science at Ulster University, for many years. Prof Saunders has led pioneering research addressing a significant knowledge gap in understanding myopia prevalence amongst children with a developmental disability. Her work has had significant impact in developing public health information relating to myopia and securing commitment for enhanced eye-care services for children in special education settings in England.

This is an area of research Ive been involved in for over 30 years, she says. Everyone is interested in myopia but research into children with disabilities is less sexy and less interesting for people. But the difference you can make to peoples lives and families is just unbelievable. Its something Im very passionate about.

Part of the problem is that we expect children to tell us if they cant see something properly. Children with learning disabilities have different ways of communicating or may not communicate at all, Saunders explains. If the child doesnt see the difference between a horse and a cow it can be put down to their learning disability rather than a sight defect. People have low expectations of the children and the problems are attributed to their underlying disability, whereas the child may have difficulty seeing colours, focusing and so on. This results in diagnostic overshadowing and its a very big problem for children with learning disabilities.

The issue is compounded by the fact that many conditions have associated vision problems. You have to know whats normal for the particular condition. I have concentrated on Down syndrome, autism and cerebral palsy. The brain is a huge part of how we see the world.

The scale of the problem is highlighted by research carried out by UK charity SeeAbility, which found children in special schools in England are 28 times more likely to have problems with their vision and a six-year-old child with Down syndrome is 10 times more likely to have a sight defect.

Its not as simple as carrying out normal eye tests, however. Think about a child with learning disabilities and what they see when an optometrist comes up to them with a shining bright light in a dark room its quite frightening.

Saunders own research has led to significant progress in the area. The Special Education Eyecare (SEE) project, which was funded by Action Medical Research, saw a comprehensive eye-care service being provided in a special school in England to establish if it resulted in a measurable benefit.

A school is a very good setting for eye tests, Saunders says. You can do part of the test in the morning and finish it in the afternoon, so it is not overwhelming for the child.

The results, which showed clear benefits, were published in a research paper last year. The outcomes included an improvement in visual status, with more children having their visual problems managed properly and an improvement in classroom engagement. Another benefit saw parents and teachers reporting value from the in-school service and from the reports and advice they received from the eye-care professionals on each childs visual status and visual needs.

They not only understood the lay description of the vision information but used this information to help the child at home and in the classroom, says Saunders.

NHS England have used the outcomes from the SEE project in their design and implementation of a new, evidence-based in-school eye-care programme which will reach over 100,000 children each year, she adds. We are working with the Public Health Agency and the Health and Social Care Board in Northern Ireland to do something similar.

Her research has also addressed testing difficulties. I did my PhD in the University of Cardiff with Maggie Woodhouse, who is a pioneer in this area. We wanted to find a way to measure focus in an objective way.

This resulted in the development of the Ulster-Cardiff Accommodation Rule (or UC-Cube), the first commercially available tool that allows rapid, clinical assessment of focusing accuracy without the need for the patient to communicate.

The UC-Cube is a unique tool providing a standardised stimulus and measurement framework within which to conduct dynamic retinoscopy, objectively measure focusing ability and contextualise outputs against research-derived normative data.

We started out by getting the technicians in the universities to make it for us but then Maggie and I put our heads together to make it commercially available, says Saunders. All the child has to do is look at an illuminated picture and the device does the rest. It can even be used with tiny babies.

The UC-Cube is now used in countries across the world, including Australia, Sweden, South Africa, Antigua, India and the United States, with users confirming benefits to patients and clinical practice.

The next step will be to take the testing out of the special school setting. Once we have comprehensive eye-care services up and running in special schools, we will try to prove if it works for children in mainstream schools. More and more children with learning disabilities are being educated in mainstream settings.

Read the original post:
Bringing the benefits of eye-care to vulnerable children - The Irish Times

Read More...

Coronavirus: Life in lockdown when you are blind – BBC News

Sunday, April 26th, 2020

As social distancing restrictions continue due to the coronavirus there are extra challenges for those who are blind or have sight loss.

Louise Neeson has limited vision and is registered blind. She is originally from Maghera, County Londonderry, but now lives in Belfast with her fiance Joe, who is also registered blind.

Everybody is having difficulties receiving grocery deliveries these day and we find that exceptionally difficult," she said.

Whenever I go to the shop, Ive had the experience of there being a queue outside and not realising.

Meanwhile Debbie Shaw from Randalstown has had some initial difficulties getting her guide dog much needed exercise.

Debbie was born with albinism, which causes her eyes to be light sensitive and in recent years her eyesight has deteriorated to the point where she requires the aid of her guide dog, Frizz.

However, her underlying health conditions means she has had to self-isolate, which has limited Frizzs time outside.

She has had to look to local volunteers for a solution.

The Royal National Institute for the Blind (RNIB) helpline number: 0303 123 9999

Video journalist: Niall McCracken

See the rest here:
Coronavirus: Life in lockdown when you are blind - BBC News

Read More...

Page 7«..6789..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick